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ABSTRACT
Alzheimer’s disease (AD) is commonly characterized by a loss of cognitive function due to the
deterioration of neuronal synapses from the presence of senile amyloid beta-42 (Aβ42) plaques.
Evaluating cognitive deficits caused by Aβ42 using human cortical neurons poses a challenge due
to sourcing difficulties, and the use of animal models to assess drug efficacy creates biological
hurdles from lack of species translatability. Recent advances in induced-pluripotent stem cell
technology have enabled the development of mature, human-based cortical neuron models. The
development of an hiPSC-cortical neuron differentiation protocol facilitates the exploration of
disease onset and functional analysis from a patient-derived cell source, and further investigation
of potential therapeutic treatments, while eliminating biological efficacy concerns. Long-term
potentiation (LTP) was utilized as an in vitro correlate for memory and learning to quantify
cognitive deficits in sporadic AD (SAD) and familial AD (FAD) systems and assess drug
treatments for the prevention of Aβ42-induced neurotoxicity. Synaptic connectivity and LTP
induction through high-frequency stimulation was simulated through cortical neurons cultured on
microelectrode arrays (MEAs), such that the functional activity of the neuronal population could
be assessed overtime. AD therapeutic treatments were shown to block the Aβ42-induced
neurotoxic loss of synaptic plasticity and maintain persistent LTP in a model for SAD.
Subsequently, FAD was assessed through the differentiation of patient-derived AD iPSCs, where
LTP proficiency could be evaluated to relate to clinical cognitive evaluations. This study
established a serum-free, in vitro human-derived iPSC-cortical neuron protocol that could be
adapted to validate disease mechanisms and drug efficacy in patient-derived neural networks as a
potential platform for precision medicine.
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CHAPTER ONE: INTRODUCTION
OVERVIEW OF ALZHEIMER’S DISEASE
Alzheimer’s disease (AD) affects an estimated 6 million individuals over the age of 65 and
is the most common form of dementia [1]. AD is notable for its characteristic loss of cognitive
function. Its symptoms commonly include detrimental effects on patient’s memory, learning, and
focus [2]. Its onset is considered to either be familial through genetically inherited mutations, or
sporadic from the formation of senile plaques due to environmental factors. On a biological level,
AD is caused by synaptic dysregulation leading to the deterioration of neural networking and
neuronal cell death [3]. There are several hypotheses speculating the biochemical mechanisms
leading to AD pathology, including amyloid beta-42 (Aβ42) plaque accumulation [4],
hyperphosphorylated Tau neurofibrillary tangles (NFTs) [5], neuroinflammation [6, 7], oxidative
stress [8, 9], cholinergic burden [10, 11], and Ca+2 dysfunction [12]. The most widely studied
postulations for the onset of AD are the accumulation of Aβ42 oligomers to form neurotoxic
plaques and NFTs of hyperphosphorylated tau.
One hypothesis on the major mechanism of the prominent synaptic dysfunction of AD is
through the accumulation of Aβ42 plaques in the synaptic cleft causing excitotoxicity [13],
inflammation [6, 14], and physical deterioration of neural networks [15]. The formation of Aβ42
is a direct result of the improper cleavage of Aβ40 from amyloid precursor protein (APP) [16].
The physiological function of Aβ40 is neural growth and repair, and it is mainly responsible for
the appropriate differentiation of neurons from neural progenitor cells [17]. Aβ40 oligomers
become neurotoxic when they are extended by 2 additional C-terminal residues, which can happen
from the failure of the gamma secretase complex to cleave APP to Aβ40 at its cleavage site, leading

the Aβ42 oligomerization [16]. Once extended into its neurotoxic form, Aβ42 oligomers cluster to
form plaques, which can agglomerate and cause detrimental effects on neuronal networking and
several post-synaptic receptors, such as the NMDA and AMPA receptors responsible for glutamate
binding in synapse transmission [18, 19]. The major role of astrocytes in the synaptic network is
proper glutamate reuptake and recycling, which can also be disturbed in the presence of the plaques
[20]. Additionally, the accumulation of Aβ42 plaques in the presence of microglia and/or
astrocytes can trigger an immune response, leading to the release of inflammatory factors such as
IL-1, IL-6, and TNF-β that can further exacerbate neurodegeneration [13, 21].
Another hypothesis of synaptic dysfunction in AD is through the accumulation of Tau
neurofibrillary tangles. Tau in its benign form is responsible for microtubule stabilization and
axonal transport [22]. When the Tau tubule proteins become hyperphosphorylated, the axonal
stabilization is disrupted, leading to the disintegration of the axon and release of phosphorylated
Tau into the synaptic cleft, where it can accumulate into neurofibrillary tangles and further
aggravate synaptic deterioration [22, 23]. However, it has been cited that hyperphosphorylation of
Tau is dependent on the inflammatory response due to the presence of Aβ42 within the neural
network [24]. Tau neurotoxicity is predominantly an exogenous effect that is dependent on the
presence of Aβ42 in the synaptic cleft [25].
AD arises either from a familial or sporadic source. Familial AD is genetically derived,
characterized by an early onset from missense mutations in either the APP gene or the Presenilin1 or Presenilin-2 genes, the latter of which are subunits of the gamma secretase enzyme responsible
for the improper cleavage of APP leading to the formation of Aβ42 plaques and subsequent Tau
NFTs [26]. Phenotypic symptoms of FAD start clinically as early as the patient’s 20s, with the
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hyperexcitation mechanism presenting itself through seizures, preceding synaptic deterioration
from excitotoxicity and decline of the patient’s cognitive functioning [27, 28]. The apolipoprotein
E4 (ApoE4) allele has also been implicated as a cause of AD [29]. ApoE4 is one of three possible
alleles for ApoE, with an E2 and E3 variant also present. ApoE4 is thought to cause AD because
it is the least lipidated form of ApoE, meaning it has lower functioning in the transport of
cholesterol and clearance of Aβ, affecting neuronal maturation and dendritic arborization [30-32].
Sporadic AD, also considered late-onset AD (LOAD), is speculated to be environmentally driven,
taking into consideration the lesser studied mechanisms of AD, such as cholinergic burden [33],
neuroinflammation [34], and oxidative stress through ROS [35, 36].
Long-term potentiation (LTP) is a means of assessing memory and learning in models of
AD. It is a quantitative measurement of synaptic plasticity utilized as a correlate for cognitive
function in models of neurodegeneration [37]. In vitro models of LTP have either employed the
use of a dual patch-clamp technology of a probe inserted into brain tissue, measuring the EPSP
slope following tetanic stimulation [38], or use chemical or electrical high-frequency stimulation
on a microelectrode array to evaluate the neural population dynamics [39]. The elicited response
to the stimulation of enhanced neuronal firing should persist overtime, indicating a strengthening
of synaptic network integrity referred to as synaptic plasticity [40]. The enhanced activity
following chemical or high-frequency electrical stimulation triggers an increase in expression of
glutamate receptors on the cell membrane, allowing for more glutamate binding at the postsynaptic terminal and overall long-term enhanced activity within the neural network [41].
At the molecular level, synaptic plasticity occurs due to the heightening of the release of
glutamate vesicles from the pre-synaptic neuron accompanied by the increased expression of
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glutamate receptors on the post-synaptic sites, enabling the enhanced signal transmission [42]. The
AMPA and NMDA receptors are glutamate receptors implicated in synaptic plasticity. AMPA
receptors are endocytosed in response to LTP induction [43]. While the expression of AMPA
receptors is also enhanced because of LTP induction, the NMDA receptor has been more heavily
linked to neuronal LTP due to its voltage-dependent nature [44, 45]. The Mg+2 block within the
receptor is only cleared after the membrane is depolarized to a certain voltage threshold, which
can be achieved through the stimulated release of glutamate vesicles from the pre-synaptic terminal
binding to AMPA receptors. Once the Mg+2 block is released, there is a flood of Ca+2 ions into the
post-synaptic neuron [46].
Several therapeutics have been found to mitigate the synaptic dysfunction in AD through
varying mechanisms of action. Memantine, one of the most widely used AD drugs, works against
the excitotoxicity hypothesis, targeting the NMDA receptor with low-affinity binding to block the
excessive stimulation of glutamate binding that ultimately leads to neuronal cell death from
overexcitation [47, 48]. The presence of excessive glutamate contributes to long-term
overexpression of glutamate receptors, like the AMPA and NMDA receptors. Overtime, neuronal
populations experience a decrease in the release of pre-synaptic glutamate vesicles, which will not
be able to fulfill the demand of the excessive expression of NMDA receptors to achieve LTP [49].
Donepezil can work at this stage of synaptic decline to enhance neuronal stimulation through an
alternative neurotransmission pathway. Donepezil inhibits acetylcholinesterase, the enzyme
responsible for the breakdown of acetylcholine [10]. The acetylcholine neuronal pathway is
regulated by negative feedback, where it is taken up and recycled based on the necessity and
availability of acetylcholine in the synaptic cleft, and since Donepezil also binds with low affinity,
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it is released when necessary [50, 51]. While Memantine and Donepezil target the restoration of
extracellular neuronal function at the synaptic level, other drugs, such as Saracatinib and Rolipram,
work intracellularly to counteract the negative effects of Aβ42. Saracatinib inhibits the Fyn kinase,
which, in its pathogenic state, phosphorylates APP, promoting the improper cleavage of APP to
Aβ42 [52]. Fyn is also one of the kinases responsible for the hyperphosphorylation of tau.
Additionally, the pathogenic actions of the Fyn kinase are further exacerbated in a positive
feedback loop by the presence of Aβ42 plaques and Tau NFTs. Lastly, Rolipram works
intracellularly to recover the spontaneous activity of the neuron intracellularly. Rolipram inhibits
the phosphodiesterase-type 4 enzyme that breaks down cyclic AMP within the cell. As a result,
there is an increased availability of intracellular cAMP, contributing to enhanced neuronal activity
[53, 54].
Currently, there is a gap in combining human-derived neuronal models of AD with
functional, in vitro surveying of the integrity of neural networks. The ability of microphysiological
systems (MPS) to explore neuronal responses to the addition of compounds, including
neurotransmitters and receptor inhibitors, enables for the inquiry of biological mechanisms
contributing to neurological disorders. While many AD models have been developed, mouse
models are limited biologically by the species gap, and many human in vitro models either lack
functional evaluation of a purely glutamatergic neuronal culture or employ the use of undefined
serum. The integration of human-iPSC technology in combination with MPS provides a humanbased system capable of functional analysis as a platform for preclinical drug evaluation.
Induced pluripotent stem cells (iPSCs) are reprogrammed stem cells that can subsequently
be differentiated into any somatic cell type [55]. This technology is advantageous because of its
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low-invasive sourcing, with induction of stemness and pluripotency from either a skin biopsy of
fibroblasts or peripheral blood mononuclear cells (PBMCs) [56]. These reprogrammed stem cells
possess stemness properties, meaning they are self-renewing and can proliferate indefinitely [57].
Consequently, iPSCs provide a source for studying biological mechanisms and the onset of
diseases where human sources are difficult to acquire, such as central nervous system (CNS)
diseases. This allows for developing human-based in vitro models because of its retention of source
DNA, enabling the cultivation of patient-specific disease models and therapeutic treatments [58].
Not only is it a feasible source of analyzing neuronal networking in human-derived cortical neuron
cultures in vitro, but genetically-based neurological disorders can also be explored upon the
development of an hiPSC-cortical neuron differentiation protocol. Once differentiated and
established, iPSC-cortical neurons can be utilized in MPS to evaluate the functional properties of
the neuronal population.
The establishment of an hiPSC cortical neuron model capable of assessing LTP through
synaptic connectivity fill the gap not only for a species relevant, mature neuronal model of
cognition, but also provides a system for in vitro, preclinical drug evaluation. This study will cover
the derivation and characterization of a protocol to develop mature hiPSC-cortical neurons and
illustrate their response to chemical compounds and electrical stimulation for biological efficacy.
Furthermore, this model was utilized to evaluate the inhibition of LTP persistence in the presence
of Aβ42 oligomers, which could be blocked through the co-administration of the neurotoxic
oligomers with cited AD therapeutic compounds. Functional deficits in FAD neuronal cultures
were also investigated following the differentiation of cortical neurons from AD patient-derived
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hiPSCs. The validation of this model combining hiPSC and MEA technology paves a path for
further exploration of mechanisms of CNS disease onset and treatment efficacy.
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CHAPTER TWO: A FUNCTIONAL HIPSC-CORTICAL NEURON
DIFFERENTIATION AND MATURATION MODEL AND ITS
APPLICATION TO NEUROLOGICAL DISORDERS
Introduction
Functionally mature human cortical neuron in vitro models are needed for investigating
numerous CNS diseases, including Alzheimer’s, Parkinson’s, Huntington’s, epilepsy, brain injury
[59] and for subsequent drug development [60-62]. The use of iPSCs provides phenotypic
relevance in vitro because of the physiological accuracy of using human cells as opposed to animal
models by eliminating the species gap [63]. IPSC lines can be established through the
reprogramming of adult cells such as fibroblasts and blood cells. IPSCs can be propagated
indefinitely, and their pluripotency easily lends itself to the differentiation of multiple cell types.
This is particularly useful for modeling CNS diseases, because of the characteristic lack of
proliferation in primary neurons, the difficulty harvesting and maintaining human neurons in vitro,
and the ability to separately differentiate neurons, astrocytes and microglia. The establishment of
iPSC-derived cortical neuronal cultures without glia would enable the further investigation of
neuronal behavior where astrocytes and microglia could be used as variables to understand their
influence in disease phenotypes.
To date, only few studies have reported successful differentiation of cortical neurons from
either embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) [64-67], and only
one demonstrated synapse formation in the in vitro system, but in serum-containing medium [67]
or in astrocyte co-culture [68]. Synapse formation and subsequent neuronal interactions, especially
induction of long-term potentiation (LTP), is the typical hallmark indicating functional circuit
formation as seen previously in slice cultures and animal models [69-71]. The ability of neurons
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to maintain elevated firing rates for extended time periods following a high-frequency electrical
stimulation protocol is correlated with learning and memory [72]. Cortical neural circuits
composed of mature cortical neurons could be more effective in modeling CNS functional
impairment such as cognitive deficits in AD or dementia, both as pure cultures or with the addition
of glia. One report of the induction of LTP in iPSC-derived cortical neuronal culture used coculture from rat primary cortical astrocytes during differentiation, which is undefined and
introduces nonhuman components to the process [73]. A new study has demonstrated LTP in
cultures of human iPSC-derived cortical neurons and primary astrocytes but did not extensively
characterize the neuronal maturity [62]. Undefined animal components during the differentiation
procedure would limit the use of the cortical neurons in applications for clinical cell therapy and
human cell-based preclinical pharmaceutical studies. This study aimed to develop a protocol for
differentiating cortical neurons from human iPSCs in a defined xeno-free, serum-free system, and
to establish an in vitro functional human cortical neural model, free from glial cells, that with the
maturity level necessary to recapitulate LTP function and to model human cortical dysfunction.
In studies of iPSC-derived cortical neurons there is a knowledge gap concerning the level
of maturation necessary for the accurate recapitulation of physiological function for the modeling
of relevant diseases, which in many cases is determined by the level of their synaptic and functional
characteristics. Additionally, in an effort to establish the use of iPSC-cortical neurons to a level of
in vivo competency, confirmation of the exact neuronal subtype present in a culture model was
necessary. Reports on the classification of iPSC-derived cortical neurons as excitatory or inhibitory
has been cursorily examined, such as in Cao et al. in 2017 [66], but has not been well explored
longitudinally, and neither has the state of this maturation on the ability of these neurons to
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accurately model CNS diseases free of glial cell contributions. Similarly, modeling epilepsy can
be challenging due to its primary symptom of erratic firing of neuronal networks. The randomness
of these symptomatic episodes causes difficulty with in vivo studies. The employment of iPSCcortical neurons to study this neurological disease would enable not only more accurate toxicology
and efficacy modeling, but also the possibility of patient-specific treatments due to the ability to
isogenetically modify iPSCs [59].
This study presents a unique protocol for differentiating iPSCs into cortical neurons, as
well as a maturation process for obtaining functionally mature cortical neuron circuits, which was
free of astrocytes and microglia influence, that was competent for synapse formation and LTP
induction. The report described both the maturation of iPSC-derived cortical neurons and the
inhibitory/excitatory

subtype

classification

that

was

characterized

longitudinally

by

immunocytochemistry, patch clamp electrophysiological as well as microelectrode array (MEA)
analysis. The iPSC-derived cortical neuron on MEA model system was further applied to model
aspects of epilepsy and its treatment. This human-based defined cortical neuron-on-a-chip
functional system could be a valuable platform for modeling other human CNS diseases and
especially for preclinical pharmacological evaluation of therapeutic drugs.

Results
Differentiation of Cortical Neurons from hiPSCs
The differentiation of cortical neurons from hiPSCs consists of four major steps (Figure 1A). To
initiate the differentiation, two small-molecule inhibitors of SMAD signaling, LDN193189 and
SB431542, were utilized for the induction of early neural lineages [74] (DIF1). Then DKK-1, an
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antagonist of Wnt/β, which can induce telencephalic specification [75], and DMH-1, a highly
selective small molecule BMP inhibitor comparable to Noggin that can promote neurogenesis of
hiPSCs, were used [76] (DIF 2). It was postulated that the combination of these two molecules
would facilitate the induction of the rhombomeric neuroepithelia. Next, DKK-1 was withdrawn
and Cyclopamine was introduced (DIF 3). Cyclopamine, a small molecule SHH inhibitor, has been
shown to specify the dorsal cortical fate in a dose-dependent manner and enhance the generation
of cortical glutamate neurons [66]. The differentiation was completed by culturing these cells in
the presence of trophic factors BDNF, GDNF, cAMP, ascorbic acid, and laminin that support the
survival and maturation of cortical neurons [77-80] (Maturation).
Following differentiation, the iPSC-cortical neurons were characterized to confirm the
identity and level of maturation of the cortical neurons and for the presence of glial cells. Figure
1B indicates the morphological progression of the iPSC-cortical neuronal cultures. On Day 7 (left),
axonal and dendritic extensions from the neurons were observed, while on Days 14 (middle) and
40 (right), robust neuronal process extension was observed and networking morphology was
present. On Day 40, immunocytochemistry (ICC) using the layer V cortical neuron marker ctip2
[81], along with the neuronal marker β-III tubulin, to highlight neuronal processes, confirmed
cortical neuron identity (Figure 1C). To quantify the percentage of the neuronal component of the
differentiated culture, cultures at Day 40 of maturation were stained with the neuronal marker βIII tubulin as well as the neuroprogenitor and glial cell marker GFAP [82]. The results indicated
that the neuronal percentage in the culture was greater than 95% (Figure 1D). Longitudinal
expression of these markers together with ctip2 marker was further quantified using flow
cytometry, revealing that the expression of the markers ctip2 and β-III tubulin on Days 0, 14, and
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28 increased over time, being >90% at the last time point, in agreement with the ICC results, while
the expression of GFAP decreased over time to almost undetectable levels (Figure 1E). These
analyses indicated that this differentiation protocol generated a close-to-pure cortical neuronal
culture if sufficient maturation time was utilized that enables the study of neuronal only
characteristics.

Characterization of Terminally Differentiated hiPSC-Cortical Neurons Via Immunocytochemistry
Following the successful differentiation to cortical neurons, immunocytochemistry was performed
to further characterize the synapse formation by staining with the synaptic terminal protein
synaptophysin and the postsynaptic markers including GluR1 (a subunit of the AMPA
glutamatergic receptor), the NMDA receptor, and the receptor-associated molecule PICK1
(Protein interacting with C kinase 1). Day 40 cultures were utilized for this ICC analysis (Figure
2). Synaptic connectivity was observed via the co-localization of the pre-synaptic marker
synaptophysin with the post-synaptic marker PICK1 (Figure 2A). Additionally, the expression of
NMDA and AMPA receptors was demonstrated using MAP2 co-stained with the markers
NMDAR1 and GLUR1, respectively (Figures 2B and 2C). The existence of NMDA and AMPA
receptors on the neuronal cell bodies was also indicative of terminal differentiation and suggesting
functional and physiological maturity at this timepoint.

Characterization of hiPSC-Cortical Neurons Via Whole-Cell Patch Clamp Electrophysiology
Whole-cell patch clamp was used to determine the electrical properties of the iPSC-cortical
neurons at Days 14, 21, 28, and 40. Specifically, the cells were examined for ionic currents,
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induced repetitive firing, and spontaneous firing. At Day 40, the cortical neurons expressed voltage
gated Na+ and K+ channels as indicated by inward Na+ currents and outward K+ currents (Figure
3A). As the culture progressed, there was an increase in the percentage of cells showing
spontaneous and repetitive firing, indicative of increasing cortical neuron excitability and
functional maturation in the culture over time (Figures 3B and 3C). Additionally, other functional
parameters that increased significantly over time included the action potential amplitude (Figure
3D) and the Na+ inward currents (Figure 3F), while any change of the K + current over time is not
obvious (Figure 3G), suggesting the increase of action potential amplitude can be attributed mostly
to the increase in Na+ current rather than the change in the K+ current [83, 84]. Analysis of the
resting membrane potential demonstrated a progressive hyperpolarization as the culture matured
(Figure 3E).

Recording of Neural Activity on MEAs
Microelectrode array (MEA) recording technology has been a powerful tool to monitor
populational neural activity non-invasively and to analyze neurocircuit activity. In order to adapt
these electrically active cortical neurons into an MEA system, the iPSC-cortical neurons were
plated on surface patterned MEAs. Phase images in Figure 4A demonstrate an example of the
patterned distribution of cortical neurons on these MEAs. Neurons were observed to successfully
form patterns on electrodes, with neuronal bodies localized on the electrode surface, and axon
bundles forming between the adjacent electrodes. Recording of spontaneous neural activity gave
rise to representative traces as in Figure 4B. To confirm these traces were generated by neural
activity, lidocaine, a Na+ channel inhibitor and well-characterized local anesthetic, was used to
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block activity. Addition of lidocaine quickly reduced, and subsequently eliminated, neuronal
signaling within approximately two minutes (Figure 4B and 4C).
This MEA system was then utilized to investigate the progressive changes in neural activity
by measuring spontaneous activity on Days 21, 28, 35, and 40. The waveforms measured displayed
lengthening of amplitude, especially in the positive direction to emphasize the biphasic properties
as well as the sharpening of the waveform average over time (Figure 4D). Quantification of
spontaneous activity indicated an increase of neuronal activity with increasing culture time,
consistent with the patch clamp results, though non-significant (Figure 4F). Neuronal activity
remained consistent past day 40 of maturation, and as a result, it enabled experimentation on
mature neurons from older cultures. Subsequent MEA experiments were performed based on the
presence of NMDA and AMPA receptors found in previous ICC experiments, by the addition of
the chemical stimulator glutamate to increase neural activity. As in Figure 4E and G, addition of
glutamate increased the frequency of neural activity within the time window of 35-40 DIV. The
silencing and enhancement of neural activity by lidocaine and glutamate, respectively, confirmed
the validity of the MEA recording system as well as establish the expected functionality of the
terminally differentiated cortical neurons [85, 86].

Formation of Synaptic Circuits and Induction of LTP on MEAs
To evaluate neural circuit activity of the patterned cortical neurons on the MEAs, NBQX, an
AMPA receptor blocker [87], was applied to the culture and the activity was analyzed. Figure 5A
depicts representative waveform traces from baseline recordings (left) and then following dosage
with NBQX (right). As in Figure 5B, addition of NBQX induced significant reduction of recorded
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activity while there was no significant change in vehicle control. This result revealed that a portion
of activity recorded is from inputs through neuronal synapses, or there were functional synapses
formed in the iPSC-cortical neural culture.
Since LTP formation is an important property of cortical activity as well as a key
mechanism for neural plasticity and a strong cellular basis for cognition, the capability of inducing
LTP in these glial cell free cultures was investigated. In order to induce LTP, a paradigm of high
frequency stimulation (HFS) was applied to all the electrodes and the spontaneous activity of these
neurons were quantified before, right after and one hour post HFS [62]. As in Figure 5C, there was
a significant increase in neural activity after the HFS, and this increase was maintained for at least
one hour. This result indicated LTP formation in this iPSC-neural culture as previously reported
in other neuronal cultures [62, 67]. As validation, similar experiments in the presence of the AMPA
receptor antagonist NBQX were conducted in which glutamatergic synaptic activity was blocked
and no LTP could be induced. As expected, HFS did not induce any increase in activity (Figure
5D), but rather caused the same decrease following NBQX dosage observed in Figure 5B,
confirming the increase in neuronal activity following HFS was synapse-based.

Characterization of Excitatory and Inhibitory Features in Mature and Immature iPSC-Cortical
Neurons
To characterize the identity of these iPSC-cortical neurons as excitatory or inhibitory (Figure 6),
the vesicular glutamate transporter 1 (vGLUT1) was used as a marker for the glutamatergic
neurons while GABA was used to distinguish the GABAergic neuronal phenotype.
Immunocytochemical staining revealed that on Day 21 (Figure 6A), neurons were positive for both
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the excitatory neuron marker vGLUT1 and the inhibitory neuron marker GABA. Subsequently, at
Day 40 (Figure 6B), the neurons only stained positive for vGLUT1, indicating full maturation to
an excitatory phenotype as the culture progressed. This is consistent with the increased
spontaneous activity measured by patch clamp and MEA recordings in the latter days of maturation
(Days 35-40). It has been previously reported that GABA is the predominantly expressed
neurotransmitter in the early stages of brain development [88]. Consequently, GABA is imperative
for neuroprogenitor proliferation and migration in the early stages of development [89], with
GABA being cited to have excitatory properties of neurotransmission at the immature stage of
development before the shift to the utilization of glutamate as the excitatory neurotransmitter [90].
This observation implied a reduced capability of inducing LTP in younger cultures. This
hypothesis was then tested in culture at Day 21 compared to that at Day 35. As in Figure 6C, with
additional waveforms depicted in Figure S1, LTP could be induced at Day 21 culture, but did not
persist after one hour. However, one hour LTP persistence was achieved with the addition of
picrotoxin to block inhibitory signals. When neurons were past Day 35 in culture as characterized
as purely glutamatergic in Figure 6, and LTP was seen to persist at one hour following LTP
induction without inhibiting the GABAergic signaling. This result reproduced the previous
findings that modulating the percentage of inhibitory signaling in cortical neuron circuits is an
important parameter for successful induction of persistent LTP [91].

The Induction and Quieting of Epileptiform Activity in Immature Cortical Neurons
The above analysis indicated a significant amount of GABAergic signaling in cultures younger
than Day 40, as well as the efficiency of modulating the neurocircuit activity by regulating the
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GABAergic pathway. This iPSC-cortical neuron culture at earlier days thus potentially could
provide an appropriate platform for modeling epilepsy or seizures, in which one or more parts of
the brain has a burst of abnormal electrical signals that interrupt normal brain activity.
Additionally, the usage of mixed inhibitory and excitatory neuronal co-cultures for CNS diseases,
such as epilepsy, has previously been reported in the literature [92, 93]. To explore this potential
application, neural activity was modulated chemically to induce and quiet epileptiform activity in
immature, Day 21 cortical neurons (Figure 7). Neural activity was enhanced by addition of 100
µM bicuculine through blocking of GABAergic signaling, and subsequently quieted following the
addition of the epilepsy suppression drug valproic acid (1 mM). Representative waveforms are
shown in Figure 7A depicting baseline activity, the increase in firing following the addition of
bicuculine and subsequent elimination of activity following dosage with valproic acid. Figure 7B
is a graphical representation of the quantified firing frequencies normalized to the baseline activity,
further confirming these results. This result demonstrated the applicability of this system for
modeling epilepsy.

Discussion
This study aimed to establish a functional model of mature hiPSC-cortical neurons in a
serum-free environment that could be used as a platform for in vitro preclinical drug testing. By
integrating MEA technology, this system demonstrated the capability for LTP induction and neural
disease modeling for epilepsy. A primary application would be that this system can be tailored to
evaluate iPSC induced, patient-specific phenotypes for treatments for personalized medicine
applications, as we show the ability to control the level of maturation and manipulate the phenotype
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in a controlled fashion. The neuronal culture was characterized using immunocytochemistry, flow
cytometry, and whole-cell patch clamp as well as on MEAs in an organ-on-a-chip system to
determine functional maturity as the culture progressed to terminal differentiation that was free of
glial cells. Neuronal activity on MEAs demonstrated the capability for LTP induction, as well as
being conducive both chemical and electrical modulation, for the modelling of neural diseases and
drug testing. Astrocytes and microglia can be added selectively in the cultures in future
experiments to understand their influence on neuronal behavior and disease phenotypes.
This study demonstrated the longitudinal maturation process of iPSC-cortical neurons in
vitro

through

the

characterization

of

excitatory/inhibitory

neuronal

components,

electrophysiological activity of individual neurons and neuron circuits. Immunocytochemistry and
flow cytometry characterization during the maturation process indicating the gradual increase of
the percentage of cortical neurons (by ctip2 and β-III Tubulin) and the decrease of
neuroprogenitors (by GFAP). By Day 28, more than 90% of the cells were cortical neurons. Based
on patch clamp analysis, the percentage of neurons firing spontaneously and those firing repetitive
action potentials under depolarization increased over time, reaching ≥ 90% by Day 40 (Figure 3).
Correspondently, the firing frequencies recorded by MEA analysis demonstrated gradual increases
during a similar time period in culture. Our success in the differentiation of the iPSCs into a high
level of maturity and function without the need for serum, astrocytes or conditioned medium is
due to our long history of utilizing serum free, defined systems to culture pure populations of cells,
including hepatocytes [94], cardiac cells [95, 96], motoneurons [97], skeletal muscle [98] as well
as combination of the cells in multi-organ systems for up to 28 days [99].
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Long-term potentiation (LTP) has been used in research as a quantitative measurement of
cognitive functions related to learning and memory [100]. It is defined as the ability of neurons to
retain sustained, elevated firing rates following electrical or chemical stimulation [37, 62, 101]. In
vivo, LTP has been shown in mouse models as a measurement of cognition with respect to AD
[70]. Specifically, they have utilized LTP absence and deficits as the main readout following
dosage with amyloid-β42, showing toxicity from plaque accumulation [72, 102]. The induction of
LTP on MEAs has been shown previously in rat cortical neuron models [103, 104] as well as
hiPSC derived cortical neurons with astrocytes and in serum-containing medium [105, 106]. This
study demonstrated the ability of iPSC-derived cortical neurons cultured on MEAs to exhibit LTP
without glia in a serum-free medium. The ability of the culture to display LTP allows for modelling
of CNS diseases related to learning and cognitive dysfunction, which are essential functional
markers in clinical settings for neurodegenerative diseases such as Alzheimer’s disease [107],
epilepsy [108], and autism spectrum disorder [109].
The iPSC-cortical neuron-MEA system provides an ideal, non-invasive, and less labor
intensive approach than patch clamp electrophysiology to monitor neural activity, not only
verifying the aforementioned chronological maturation of the neuronal activity of the culture, but
also demonstrating controlled electrical and chemical modulation of this activity. Lidocaine, a
Na+ channel blocker and local anesthetic, [85], abolishes neuronal activity, while glutamate,
induced increased neuronal activity. Additionally, NBQX, an AMPA receptor antagonist, was used
to investigate the neural circuit properties. The significant decrease in activity following dosage
with NBQX (Figure 5B) suggests that approximately 50% of the recorded spontaneous activity
are from synaptic inputs of the AMPA receptors. Furthermore, systems that were dosed with
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NBQX (Figure 5D) indicated a significant decrease in activity following LTP induction for both
immediate and 24 hours after HFS (Figure 5C). Therefore, it can be inferred that the persistent
LTP observed in our cultures is based on the synaptic networks formed between the cortical
neurons.
One important issue of in vitro cultures is controlling and defining the status of iPSCcortical neurons as excitatory or inhibitory, which ultimately influences the ability an individual
neuron to fire action potentials and its capability of generating a cascade of neuronal firing seen in
LTP models [110, 111]. In alignment with the dual-transmitter phenomenon observed in multiple
types of neurons during early stages of brain development [112], immunocytochemical analysis
revealed that cortical neurons younger than Day 40 co-stained for both the inhibitory and
excitatory markers GABA and vGLUT1, respectively, while those older than Day 40 displayed
almost a pure vGLUT1 composition. As a result, it was expected that overall neuronal activity in
the early cultures would be low because of the presence of GABAergic neurons in the culture;
while the more functionally mature cultures would be excitatory. This hypothesis was further
reinforced by weekly whole-cell patch clamp and spontaneous MEA data, indicating that neural
activity did not reach its peak until Day 40.
The GABAA receptor inhibitor picrotoxin was used to manipulate the immature cortical
neurons for LTP induction and maintenance due to its ability to block inhibitory signal dispersion
within the synapses [113, 114]. It was discovered that, while the exclusively glutamatergic culture
at Day 40 could retain LTP induction, the mixed population of immature neurons could not
maintain the elevated firing rates after one hour, but could if the GABAergic inhibition was
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removed by picrotoxin. This study highlights that controlling the maturation level and inhibitory
component of the culture influences its synaptic capabilities important for in vitro LTP modeling.
Epilepsy is a chronic condition and occurs most commonly during childhood, and
sometimes resolves of its own accord at the time of puberty. Our cortical neuron cultures younger
than Day 40 had a significant amount of GABAergic signaling, and blocking this inhibitory
component was shown to dramatically increase neural activity. It is hard to conclude from this
study whether the high occurrence of epilepsy in young population is linked to a dysfunctional
inhibitory signaling in the CNS, but the immature iPSC-cortical neuron culture could provide a
valuable platform for simulating epilepsy by altering the inhibitory mechanism. Bicuculline has
been previously observed in vitro to induce erratic firing deemed epileptiform activity, while
valproic acid is used as a common anti-epileptic [106, 115-117]. Currently, the animal models of
epilepsy are induced using compounds kainic acid [106, 118], pilocarpine [118], and bicuculline
[106]. While there has been a recent shift toward modeling epilepsy in vitro using human cells to
compensate for the lack of species competency in these animal models, the optimization of the
neuronal culture maturation and its capability in reproducing physiological and pathological
properties is still a work in progress [63, 93, 119]. To develop an epilepsy model using these iPSCderived cortical neurons, the effects of bicuculline was evaluated on immature cortical neuron
cultures (Figure 7), because its working mechanism is to inhibit the GABAergic pathway by
blocking GABAA receptors to regulate the balance of excitatory and inhibitory signals [120].
Subsequently, valproic acid enhances GABA transmission by inhibiting the degradation of GABA
[121]. It was observed that bicuculline was sufficient to induce an epileptic-like increase in activity
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in neuronal cultures, and that the activity could subsequently be abolished following dosage with
valproic acid.
The inherent co-expression of excitatory and inhibitory neurotransmission is potentially
adaptable to other models that rely on this interplay such as autism spectrum disorder [122],
alcoholism [123], depression, and anxiety. These models could be adapted to our system due to its
ability to measure electrical activity and study both short and long-term effects of compounds.
In summary, the iPSC-cortical neuron model exhibited the inhibitory to excitatory
conversion during maturation process. By integrating with the MEA technology, it demonstrated
functional neurocircuit formation without the need for added glial cells, especially the capacity to
recapitulate LTP induction, which is an essential mechanism for neural plasticity and cognitive
capability in neurodegenerative diseases such as dementia. It also reproduced the phenotype for
epilepsy. These non-invasive functional human diseased systems would provide more clinically
translatable platform for drug testing. They are also potentially applicable to investigate drug
interactions and off-target toxicity when adapted into a multi-organ-on-a-chip system, for either
acute or chronic effects.

Materials and Methods
hiPSC-Cortical Neuron Differentiation
The differentiation of cortical neurons from hiPSCs consisted of a timeline of three stages, starting
out with the use of small molecules, and ending with an array of neuron-specific factors. HiPSCs
(Coriell ND41865) were first grown to 90% confluence in mTESR1 culture medium (Stemcell
Technologies 85850) on a surface coated with Corning matrigel matrix (Corning Life Sciences
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354230) diluted in DMEM F12 (Fisher Scientific 21041-025). To induce the differentiation, cells
received a full media change and then fed every other day with Differentiation Medium I,
Differentiation Medium II, and Differentiation Medium III, according to the differentiation
timeline featured in Figure 1A. Differentiation Medium I consisted of N2B medium (equivalent to
DMEM F12 with insulin (Millipore Sigma 407709) 20 µg/ml and 1X N2 supplement (Fisher
Scientific 17502048)) supplemented with 6 µM SB431542 (Tocris 1614), 0.1 µM LDN193189
(Fisher Scientific 605310), 2 µM DMH-1 (TOCRIS 4126), and 10 ng/mL recombinant human
DKK-1 protein (Fisher Scientific 5439-DK-010). Differentiation Medium II consisted of N2B
medium supplemented with 6 µM SB431542, 0.1 µM LDN193189, 2 µM DMH-1, and 5 µM
cyclopamine (Sigma 239803-1MG). Lastly, Differentiation Medium III (also referred to as
“Maintenance Medium”) consisted of Neurobasal (Fisher Scientific 21103049), supplemented
with 1X Glutamax (ThermoFisher 35050-061), 1X N-2 supplement (Fisher Scientific 17502048),
1X B27 without Vitamin A (Fisher Scientific 12587-010), 20 ng/mL BDNF (Cell Sciences
CRB600D), 20 ng/mL GDNF (Cell Sciences CRG400E), 200 nM Ascorbic Acid (Sigma Aldrich
A4403), 1 µM cAMP (Sigma A6885), 1 µg/mL Laminin (Fisher Scientific 23017015), and 1X
Antimycotic-Antibiotic (Fisher Scientific 15240062).

Culture Surface Coating for Cortical Neurons: DETA Surface Coated with Poly-LOrnithine/Laminin Protein Adsorption Surface Coating
The surface for coverslips was first coated with self-assembled monolayer (SAM) DETA as
described in [124]. Further surface modification on DETA coated surfaces was achieved by
immersing the coverslips in 0.01% Poly-L-Ornithine (PLO) (Sigma Aldrich 27378-49-0) at room
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temperature for 2 hours. They were then rinsed 3 times with 1X PBS (Fisher Scientific 70013032), followed by the addition of 3.33 g/mL laminin diluted in 1X PBS. Surfaces were left at 4°C
overnight, and subsequently warmed at 37°C for 1 hour prior to the removal of laminin for cell
seeding. Patterned surface on MEA was generated by the photolithography combining cell
permissive SAM DETA and nonpermissive SAM PEG [125]. The patterned surface was further
coated with PLO/Laminin as described above.

Cortical Neuron Plating and Maintenance
Following differentiation, cortical neurons were harvested using 0.05% Trypsin-EDTA
(ThermoFisher 15400054) and neutralized by Trypsin inhibitor (Fisher Scientific 17-075-029).
Cortical neuron stocks were cryopreserved in 10% DMSO (Sigma Aldrich D4540). Individual
vials were thawed using a drop-by-drop method with cold 1X PBS. Cells were then centrifuged at
260g for 3 minutes, and seeded on coverslips at a plating density of 150 cells/mm2 and on MEAs
at 500 cells/mm2. Cells were and maintained for one week in Maintenance Media. After one week,
cells were further maintained in BrainPhys Neuronal Media Kit with SM1 and N2 Supplement A
(Stemcell Technologies 05793) that was further supplemented with 20 ng/mL BDNF, 20 ng/mL
GDNF, 200 nM Ascorbic Acid, 1 µM cAMP, 0.5 µg/mL Laminin, and 1X Antimycotic-Antibiotic.
Cell maintenance consisted of a half-media change twice weekly from the time of seeding for the
duration of the culture.
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Immunocytochemistry
Cells were fixed in 4% paraformaldehyde for 15 minutes followed by three washes with 1X PBS.
Cells were permeabilized in 0.1% Triton for 10 min and subsequently blocked 1 hour in a blocking
buffer solution containing 0.5% BSA and 5% goat serum diluted in 1X PBS, then incubated with
primary antibodies diluted in blocking solution at 4°C overnight. Primary antibodies used for
characterization included vGLUT1 (Sigma Aldrich AB5905), GABA (Sigma Aldrich A2052),
Beta-III Tubulin (Millipore AB9354), GFAP (Sigma Aldrich AB5804), Synaptophysin (abcam
ab8049), PICK1 (Santa Cruz 9541), NMDAR1 (ThermoFisher MA1-2014), and GLUR1
(Millipore AB1506). Following rinsing, coverslips were then incubated with secondary antibodies
diluted at 1:250 in blocking solution at room temperature for two hours. Coverslips were then
washed and mounted using a Gold Antifade Reagent with DAPI (Fisher Scientific P36931) and
imaged on a spinning disk confocal microscope.

Flow Cytometry
Cells were lifted using accutase (ThermoFisher 00-4555-56) and resuspended following
centrifugation in FACS buffer containing 1% BSA diluted in PBS. Further methodology for this
method is described in Patel et al [126]. Cytometry analysis was performed for the following
antibodies: Live-Dead (using Draq7), ctip2, Beta-III Tubulin, and GFAP. Expression levels were
determined by gating based on fluorophore wavelengths for cells of interest (live cells excluding
dead cells and debris).
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Whole-Cell Patch Clamp Electrophysiology
Measurement of spontaneous firing, repetitive firing, and ionic currents were achieved through
whole-cell patch clamp. Each experiment was repeated 3 times per timepoint, and 3 cells were
patched per experiment for a total of 9 cells per data point. Cells were recorded in a recording
chamber filled with Brainphys medium (buffered with 10 mM Hepes with ~300 mOsm/ kg,
maintained at room temperature (22-25oC). Patch clamp methodology was performed as described
in Caneus et al [62].

Microelectrode Array Recordings and LTP Induction
Cells were cultured on custom TiN electrode chips containing 10 electrodes, each 80 μm diameter,
spaced at between 1000 and 1500 μm. The chips were coated with DETA [127] followed by a
Poly-L-Ornithine (PLO) and laminin protein adsorption coating. Cells were seeded at a density of
500 cells/mm2 and maintained for 28 days before neuronal activity could be recorded using a
Multi-Channel Systems (MCS) rig. Spontaneous activity was recorded for 5 minutes prior to the
induction of long-term potentiation (LTP) via electrical stimulation using a high-frequency
stimulation (HFS) protocol: 10 repetitions of 4X biphasic 500mV, 5ms pulses [69]. All recordings
were taken for a duration of 5 minutes unless otherwise specified.

MEA Recording Analysis
Analysis of waveform shape and firing rate were done by filtering raw data with a 100 Hz highpass filter and superimposing all spikes surpassing -5 standard deviations from the mean of the
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noise [128]. Raw electrode data recorded from customized MEA chips was filtered using a
Butterworth 2nd order 100Hz high-pass filter. Subsequently, spikes occurring at the same
microsecond on more than two electrodes were deemed as artifacts and removed. Artifacts were
identified and removed by filtering out events that occurred at the same timestamp across multiple
electrodes. It has been observed that transient noise effects tend to co-occur simultaneously across
multiple electrodes, whereas coupled biological events (such as co-firing neurons) co-occur at
timestamps that are very close, but which are not identical to each other. Removing events across
multiple electrodes with the same timestamp has not been observed to impede the detection of
biological activity, as identified by identifying the activity that is removed when neural signaling
is abolished by administration of a compound such as lidocaine. Following filtering, electrodes
with a firing frequency lower than 0.1Hz were removed from analysis. The statistical analysis was
performed on data collected over at least 3 independent experiments, with specific statistical
methodology indicated in the manuscript. These include one-way ANOVA followed by Fisher's
LSD and Student's T test, depending on the experimental design for each dataset.

Compound Preparations
All compounds except lidocaine were prepared in 0.1% DMSO diluted in BrainPhys Neuronal
Medium at a working concentration of 10X final desired concentration. Lidocaine was dissolved
in sterile water. Compounds used for chemical modulation of neuronal activity included
glutamate (Aldrich 855642), lidocaine HCl (Sigma L5647), NBQX (Tocris 0373), picrotoxin
(Tocris 1128), bicuculine (Sigma 14340), and valproic acid (Sigma P4543-25G).
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Figures

Figure 1: Characterization of hiPSC-cortical neuron maturation via phase microscopy,
immunocytochemistry, and flow cytometry. A) Timeline detailing the differentiation process from
hiPSCs to cortical neurons. B) Phase images depicting cell morphology on Day 7 (left), Day 14 (middle),
and Day 40 (right). C-D) Immunocytochemistry of cortical neurons stained for β-III Tubulin and ctip2
(D40) in (C) and for β-III Tubulin and GFAP(D28) in (D). E) Graph of flow cytometry data on Days 0, 14,
and 28 illustrating neuron maturation by the expression of layer V cortical neuron marker ctip2, neuronal
marker β-III Tubulin, and glial cell marker GFAP, Error bar: SEM. N = 3 independent experiments. Scale
bar = 50 μm.
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Figure 2: Characterization of mature hiPSC-cortical neurons (D40) via immunocytochemistry. A-C)
Immunocytochemistry of Day 40 cortical neurons stained for pre-synaptic marker Synaptophysin postsynaptic marker PICK1 (A), for neuronal microtubule marker MAP2 and AMPA receptor marker GLUR1
(B), and for neuronal microtubule marker MAP2 and NMDA receptor marker NMDAR1. Scale bar = 50
μm.
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Figure 3: Electrophysiological characterization of hiPSC-cortical neurons via whole-cell patch clamp.
A) Representative traces of spontaneous firing (top), depolarization-induced repetitive firing (middle), and
Na+ and K+ currents (bottom) recordings from Day 40 neurons. B-C) Percentage of cells experiencing
spontaneous firing (B) and repetitive firing (C), indicating maximal activity at Day 40. D-E) Quantification
of action potential voltage (D), mean inward Na+ current (E), indicating maximum level at Day 40.F-G)
Quantification of resting membrane potential (F) and mean K+ outward current (G). Statistical analysis was
performed using one-way ANOVA followed by Tukey’s test, * p<0.05, ** p<0.01, *** p<0.001. Error bar:
SEM. N = 9 cells total from 3 independent experiments.

30

Figure 4: Microelectrode array (MEA) neuronal patterning and signal validation. A) Phase images
showing neuronal patterning on electrodes at day 40. B) Representative waveforms of spontaneous
activity on a single electrode on day 75 at baseline, immediately following vehicle control, and with 1mM
lidocaine. C) Graphical representation of neuronal firing frequency during the lidocaine dosing experiment
outlined in B. D) Representative waveforms of spontaneous activity on a single electrode on days 28, 35,
and 40 indicating increasing maturation. E) Quantification of MEA recordings indicating neuronal firing
frequency during cortical neuron maturation over 40 days. F) Representative waveforms of spontaneous
activity on a single electrode on day 75 during pre- (left) and post-dosage (right) with 100M glutamate.
G) Graph representation of neuronal firing frequencies during the glutamate dosing experiment outlined in
F. Statistical analysis was performed using one-way ANOVA followed by Tukey’s test or Student’s t-test,
* p<0.05, ** p<0.01, *** p<0.001. Error bar: SEM. Scale Bar = 50 m.
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Figure 5: Microelectrode array recordings confirming synaptic connectivity via dosage with NBQX
and LTP induction. A) Representative waveforms of spontaneous activity on a single electrode on Day
75 during pre- (left) and post-dosage (right) with 25 µM NBQX. B) Graph representation of neuronal firing
rates normalized to baseline activity before and after control 0.1% DMSO or 25 µM NBQX dose. C) Graph
of normalized firing rates of control dose of 0.1% DMSO, and following LTP stimulation immediately and
1 hour after dosage, normalized to post-dose, pre-LTP baseline. D) Graph of normalized firing rates of 25
µM NBQX-dosed, and following LTP stimulation immediately and 1 hour after dosage, normalized to postdose, pre-LTP baseline. Statistical analysis was performed using using a Kruskal-Wallis test followed by
Dunn's multiple comparisons test, * p<0.05, ** p<0.01, *** p<0.001, ****p<0.0001. Error bar: SEM. N =
10 electrodes from 3 individual experiments.
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Figure 6: Confirmation of excitatory and inhibitory character in mature and immature iPSC-cortical
neurons. A-B) Immunocytochemistry cortical neurons stained for vGLUT1 (green) and GABA (red)
indicating the neurons are expressing both excitatory and inhibitory markers at Day 21 (A), but are typically
glutamatergic at D 40. C) Quantitative MEA analysis of LTP induction for Day 21 and D35 neurons. LTP
induction in D21 neurons did not persist in after 1 hour when dosed with vehicle control but did so when
dosed with 100 µM picrotoxin prior to LTP induction, while was similar to those observed in innate Day
35 neurons without any picrotoxin addition. All the data were normalized to the Day 21 undosed baseline.
Statistical analysis was performed using one-way ANOVA followed by Tukey’s test, * p<0.05, ** p<0.01,
*** p<0.001. Error bar: SEM. Scale bar = 50 μm, N = 10 electrodes from 3 individual experiments.
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Figure 7: The induction and quieting of epileptiform activity via dosage with bicuculine and valproic
acid in immature (21 DIV) cortical neurons. A) Waveform representations of baseline activity (left), 100
µM bicuculline dosed (middle), and 1 mM valproic acid (right)-dosed systems. B) Graphical representation
of immature the firing rates normalized to baseline. Statistical analysis was performed using one-way
ANOVA followed by Tukey’s test, * p<0.05, ** p<0.01, *** p<0.001. Error bar: SEM. N = 10 electrodes
from 3 individual experiments.
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CHAPTER THREE: A HUMAN-BASED AD MODEL UTILIZING HIPSCDERIVED CORTICAL NEURONS ON MEAS FOR HIGH THROUGHPUT
DRUG SCREENING
Introduction
Today, a majority of prospective new drug candidates that showed great promises in
preclinical studies failed in clinical trial [129-133]. This disparity can be attributed in part to the
types of experimental models used during preclinical studies for assessing drug safety and efficacy
[134, 135]. These shortcomings, especially as they are related to the limitation of biological
models, underscore the urgent need to develop better approaches and models that will improve the
drug discovery and development process. To date, animal models are the most commonly used
models for scientific research and drug screening at the preclinical stage [129]. While animal
models are vital and play key roles in scientific research, they are, however, limited due to
interspecies differences, which can lead to many inconsistencies in basic research, preclinical
assessment, and clinical trials [136-139]. For instance, many diseases, such as AD, which is
associated with APP/Aβ, Tau and APOE dysregulation, are affected by several genetic factors. As
such, it is very difficult to establish human-specific disease models using other organisms [140,
141]. Therefore, the need to have more suitable and compatible models that can better replicate
human disease physiology and phenotypes and predict drug effects (e.g., toxicity, efficacy) is of
the utmost importance.
Advances in the development and utilization of human cells derived from induced
pluripotent stem cells (iPSCs) now offer a unique opportunity to create more appropriate biological
systems to model human diseases for in vitro study [142-145]. Further, those models, when
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incorporated with other technologies, such as microelectrode arrays (MEAs), have the potential to
be even more significant by offering advantages to developing better preclinical and functional
models for drug screening [146] [147]. Additionally, progressions made in biomaterials have now
made it possible to design and create physiologically-relevant microphysiological systems (MPS)
[148, 149] that provide a more relevant and representative human-based platform for accelerated
and large-scale drug testing of potential drug candidates and a path for early therapeutic
interventions [145].
Using cortical neurons derived from human induced pluripotent stem cells incorporated
with microelectrode array (MEA) technology, we developed a more compatible micro-physiology
system (cortical-HoAC) to study certain aspects of AD in vitro [150, 151]. Previously, using the
systems to assess neuronal cell functions, we demonstrated that the application of Aβ42 and Tau
oligomers to hiPSC-derived neuronal cultures resulted in pronounced deficits in stimulus-induced
LTP maintenance [150]. Those results, which were also confirmed by patch clamp
electrophysiology, are significant partly because they illustrated the capability of the system to
reproduce aspects of AD neuropathology. Moreover, they highlighted the system prospect as a
potential tool for long-term drug testing.
To evaluate the system’s capacity to assess the therapeutic effects of AD-related drugs and
its potential as a prospective tool in drug development, cortical human-on-a-chip (HoaC) systems
were established and treated with Aβ42 oligomers and different classes of AD-based drugs, which
included Donepezil, Memantine, Rolipram and Saracatinib. Following Aβ42 and drug dosing, the
functional activity and LTP maintenance of the cortical neurons were examined. The results
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revealed a pronounced decrease in cell activity within 1hr of Aβ42 dosing, which was blocked by
co-administration of Aβ42 oligomers and AD drugs simultaneously. These results underline the
significance and potential of the system as an applicable tool in the drug development process,
which can be employed to quickly analyze promising therapeutic compounds for translation to
clinical trials. Moreover, this system provides a foundation for the development of higher order,
more complex models, which can be used to not only study the drug effects, but also the
mechanism of action of the drugs as well.

Results
Analysis of iPSC-derived cortical neurons for the expression of AD drug targets
Several AD-related drugs from different drug classes, including Donepezil, Saracatinib,
Memantine and Rolipram were used in this study. Currently, Donepezil, Memantine, and Rolipram
are all FDA-approved drugs for the treatment of AD. Donepezil targets and binds to
acetylcholinesterase enzyme (AChE), subsequently preventing it from catalyzing the hydrolysis
of the neurotransmitter acetylcholine (ACh). Memantine binds to the NMDA receptor and blocks
the channel from opening and sequentially cell excitotoxicity by glutamate. Rolipram inhibits the
excessive degradation of cyclic AMP (cAMP) in the presence of Aβ42 by inhibiting the enzyme
phosphodiesterase type 4 (PDE4) that catalyzes its breakdown. Lastly, Saracatinib binds to Fyn
and block its action (i.e., to phosphorylate and activate other proteins). To determine whether the
drugs targets (e.g., Fyn, NMDAR, AChE, nAChRand PDE4) are expressed in the cortical neurons,
the cells were fixed and stained with specific antibodies for each marker followed by microscopy
analysis. Figure 8 illustrates neuronal morphology (Figure 8B) and alignment on patterned MEA
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chips (Figures 8A-8C). Additionally, the cells were stained positive for all the markers, including
PDE4 (Figure 8D), Fyn (Figure 8E), AChE (Figure 8F), nAChR (Figure 8G) and NMDAR (Figure
8H).

Analysis of AD-based drugs’ effects on Aβ oligomers-induced electrophysiological dysfunction in
hiPSC-derived cortical neurons
To assess the capacity of the system for evaluating drug effects and its competence as a prospective
tool for drug sceening and development, iPSC-derived neuronal cells were plated on both
coverslips and the HoAC systems and maintained for 28-35 days in culture prior to testing. On the
day of testing the cells were dosed with either Aβscr oligomers (5µM), Aβ42 oligomers (5µM) alone
or Aβ42 oligomers co-administered with AD-related drugs followed by incubation. At 1h (HoAC)
and 24h (patch) post-dosed, neuronal function was recorded and analyzed. Patched cortical
neurons displayed a marked decrease in cellular activity, including a decrease in sodium currents
(Figure 9A), lower or lack of induced (Figure 9B) and membrane potential (Figure 9C) in the
samples treated with Aβ42 oligomers relative to samples treated with Aβscr or co-treated with Aβ42
oligomers together with AD-based drugs at 24h post-treatment. To examine cell activity with the
cortical-HoAC systems, first, the baseline (i.e., spontaneous) activity (Figure 9D) was taken prior
to dosing followed by stimulation using a high frequency stimulation (HFS) to induce LTP (Figure
9E). Immediately after stimulation and recording, the cells were dosed and incubated for 1h. LTP
induction and maintenace were determined by measuring and comparing cell activity taken
immediately after and at 1h post-stimulation (Figure 9F) relative to baseline activity in both
samples dosed with Aβ oligomers only or in combination with AD-related drugs. As shown in
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Figure 9, the cells exhibited a pronounced increase in cell firing from baseline activity following
stimulation. The induced activity was grealty abolished in Aβ42-oligomers-treated samples but
continue to be maintained in Aβscr- and Aβ42+AD drug treated samples (Figure 9E).

Deficits in cell firing caused by Aβ42 oligomers in iPSC-derived cortical neurons is blocked by
Donepezil
A reduction in acetylcholine neurotransmitters in the brain, due in part to its breakdown and
degradation by the actetylchonlinesterase enzyme, has been implicated in the development and/or
progression of Alzheimer’s disease pathogenesis [152, 153]. Donepezil is an acetylcholinesterase
inhibitor drug and has received FDA approval for the treatment of AD [153]. To evaluate the
cortical-HoAC system proficiency to assess drug effects and its potential as a prospective tool for
drug screening, the effect of Donepezil was analyzed in this system for its therapy of AD-relevent
phenotypes, which is generated by Aβ42 oligomers as desribed above. Donepezil was used together
with Aβ42 oligomers to dose neuronal cultures. The effects of Aβ42 and Donepezil on hiPSCderived cortical neuron activity were measured both extracellularly using our cortical-HoAC
systems and intracellularly by patch electrophysiology at 1h and 24h post-treatment respectively.
As the results shown in Figure 10, the administration of Aβ42 oligomers to the cultures resulted in
a stark decrease in cell firing potential. Notably, a significant decrease in both sodium and
potassium currents was observed in cells exposed to Aβ42 oligomers compared to Aβscr oligomertreated cells (Figure 10A). Additionally, the data revealed a pronounced reduction and sometimes
a complete lack of activity of both action potential and spontaneous firing in the cells dosed with
Aβ42 oligomers relative to samples dosed with Aβscr oligomers or co-treated with Aβ42 and
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Donepezil (1µM) simultaneously (Figure 10B-10D). Electrical stimulation of hiPSC-derived
cortical neurons in the cortical-HoAC systems resulted in a significant increase in cell activity (i.e.,
firing frequency). Comparable to the samples dosed with Aβscr, the addition of Donepezil together
with Aβ42 oligomers to the cultures blocked the Aβ42-induced neurotoxic effects and preserved the
stimulus-induced cell activity (Figure 10E).

hiPSC-derived Cortical neurons retained normal electrical function following co-treatment with
Saracatinib and beta amyloid (Aβ42) oligomers
To further investigate the neuroprotective effects of Saracatinib against Aβ42 oligomers
neurotoxicity and confirm the cortical-HoAC results, the cells were plated on coverslips and
treated with Aβ oligomers with or without the Saracatinib treatment in parallel experiments. The
neuronal functional activity was measured intracellularly by whole cell patch electrophysiology.
Comparable to the results obtained with the HoAC systems, the addition of Aβ42 oligomers to the
cortical cultures resulted in prominent cell dysfunction within 24h post-dosing, including reduced
currents (Figure 11A), induced potential amplitude (Figure 11B) and spontaneous firing (Figure
11C-D) compared to Aβscr-treated samples. In sum, the data suggests some protective effects by
Saracatinib against Aβ42 toxicity in cortical cultures. To investigate whether Saracatinib offers
some protective effects against Aβ42-induced neurotoxicity, cortical-HoAC systems were
established and co-treated with Saracatinib together with Aβ42 oligomers. The cells were dosed
with either Aβscr or Aβ42 oligomers with or without Saracatinib (10nM) immediately after
stimulation, followed by incubation at 37°C and 5% CO 2. Subsequently, at 1h post-dosing and
incubation, the systems were tested for cell activity. As indicated in Figure 11E, the cells exhibited
40

a significant increase in firing frequency from baseline activity following stimulation (PostStim).
The induced activity was significantly diminished in the samples dosed with Aβ 42 oligomers
relative to Aβscr-treated samples at 1h post-dosed. However, simultaneous administration of
Saracatinib together with Aβ42 oligomers inhibits the Aβ42-induced deficits in cell firing and
preserved the induced cell activity in the Aβ42-drug treated samples compared to Aβ42 only treated
samples (Figure 11E). Further, these findings highlight the potential of the cortical-HoAC system
to assess drug effects on neuronal cultures and its potental as a prospective tool for use in the drug
development process.

Effects of Memantine on AΒ42-induced neurological defects in iPSC-derived neuronal cells
activity
To further evaluate the effects of Memantine on Aβ42-induced cell defects, the cell were treated
for 24hrs and analyzed by whole-cell patch electrophysiology. Based on the results demonstrated
in Figure 12, the application of Aβ42 oligomers to the cultures greatly abolished most of the
neuronal activity, including cell currents (Figure 12A), induced potential amplitude (Figure 12B)
and spontaneous firing (Figure 12C-D), in comparison to samples treated with Aβscr or co-treated
with Aβ42+Memantine.To assess the protective effects of Memantine in AD and against the
neurotoxic effects of Aβ42 oligomers, neuronal cell cultures (both cortical-HoaC systems and
coverslips) were established and maintained for 28-35 days in culture prior to testing. On the day
of treatment and testing, the systems were dosed either with AB scr, Aβ42 oligomers alone or Aβ42
plus Memantine following stimulation. Subsequently, after 1h post-dose and incubation at 37°C
and in 5% CO2, the samples were tested and analyzed for cellular activity. The results
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demonstrated a marked increase in cell firing frequency from baseline recording following
stimulation in all the samples (Figure 12A). Whereas the samples treated with Aβscr oligomers
continued to maintain this activity at 1h after dosing, the samples treated with Aβ42 oligomers
demonstrated a prominent decrease in cell activity from post-stimulation recording. However,
although not statistically significant, Memantine demonstrated an ability to inhibit the Aβ 42induced deficits in cell activity (Figure 12A). In all, these findings show the effects of Memantine
to block some Aβ42-induced neurotoxicity and indicate the ability and potential of the system to
measure drug effects.

Co-treatment of hiPSC-derived cortical neurons with Rolipram suppresses the neurotoxic effects
of Aβ42 oligomers on electrical function
Rolipram hampers the degradation of intracellular cAMP by inhibiting phosphodiesterase type 4
(PDE4) [154]. An increase in intracellular cAMP levels has been cited to increase the action
potential frequency of excitatory cholinergic neurons. Whole-cell patch clamp results revealed the
potential of Rolipram to prevent neurotoxic effects of Aβ42. Though not significant, the coadministration of Rolipram along with Aβ42 oligomers for 24hrs blocked sodium current deficits
observed in Aβ42 only condition (Figure 13A). Rolipram did, however, significantly block deficits
in spontaneous firing frequency and amplitude (Figure 13B-D) [155]. To evaluate the
neuroprotective abilities of Rolipram against Aβ42, cortical-HoAC systems were first maintained
for 28-35 days. For treatment and evaluation, the systems were stimulated via HFS following
baseline recording, then dosed and incubated at 37°C and in 5% CO2 prior to assessment of LTP
persistence at 1hr. Rolipram was observed to have neuroprotective effects, as co-administration of
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Rolipram with Aβ42 oligomers caused a highly significant increase in the neuronal event rate at 1h
following LTP, consistent with the persistent LTP observed in the Aβ scr treated condition. In
contrast, the systems dosed with only Aβ42 oligomers had a significant decrease in activity at 1hr
post-stimulation (Figure 13E). Overall, Rolipram was observed to inhibit the neurotoxic effects of
Aβ42 oligomers in a matter consistent with the mechanism of action of the drug.

Discussion
The drug discovery and development process has been an area of great interest to scientists
both in academia and pharmaceutical companies [156-158]. Yet, despite the significantly large
investments being dedicated towards drug discovery and development [159-162], the process
remains stagnant and inefficient, with less than 15% of all promising new therapeutic compounds
receiving marketing approval [131, 135]. This paucity is even more striking for neurological
disorders [163, 164]. For instance, it had been more than 18 years since the last drug was approved
for AD treatment, before the recent approval of Aducanumab by the FDA [165-168]. Nevertheless,
during that same period, there have been many candidate drugs that showed great promises in
preclinical studies but failed in clinical studies [163, 169, 170]. While there may be many factors
that contribute to the high attrition rate of investigative drugs, preclinical models, especially animal
models, are believed to be the predominant reason, where efficacy (52%) or safety (24%) accounts
for the majority of drug failures in clinical trials [171]. Historically, the drug discovery process
has relied largely on animal models for toxicology (i.e., safety and efficacy) research in order to
obtain preclinical evaluation of promising new therapeutic compounds [134, 172, 173]. However,
genetic differences between animals and humans is regarded as one of the main factors
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contributing to the very high attrition rate in human studies [129, 134, 139]. The lack of compatible
models to study human diseases has greatly impeded the drug development process. The limitation
of animal models combined with recent advances in the development and differentiation of iPSC
into mature cells now provide a new source [146, 151] and endless possibilities to create more
relevant models. Today, based on the relative ease with which different types of human cells
(especially neuronal cells, which are normally inaccessible for scientific research prior to death)
can be generated from iPSC cells, many researchers are re-evaluating their research approaches
and putting more emphasis towards developing more compatible, iPSC-derived-cells-based in
vitro models to study human diseases and for drug development [174]. Previously, we generated
a human-based (cortical-HoAC) system using cortical neurons derived from iPSC to study aspects
of AD pathophysiology [150]. Here, using a subset of different classes of FDA-approved, ADrelated drugs, the system’s capacity and potential for investigation as a potential platform for drug
screening. As indicated in the results above, a significant increase in cell firing frequency from
baseline activity was detected in the system following stimulation using a HFS protocol. This HFSinduced increase was maintained at least for 1 hour and was defined as LTP [175]. The stimulusinduced change in cell activity was subsequently abolished by Aβ42 oligomers dosing. Both
Donepezil and Memantine have been approved by the FDA as separate or a combined (Namzaric)
drug for AD treatment, [176]. Both drugs, as well as Rolipram and Saracatinib, were used
simultaneously with Aβ42 oligomers to dose the cortical systems. The Aβ42 oligomers neurotoxic
effects was inhibited in the presence of AD-related drugs. Furthermore, the results demonstrated
the system proficiency to capture drug effects using different AD-related drugs simultaneously
with Aβ42 oligomers.
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While more studies are needed to expand on the findings presented here and to further
validate the effectiveness and applicability of the system as a platform for drug screening, the
findings, nonetheless, provide evidence to support the utility of the system as a more relevant
human-based in vitro system to model human disease at the preclinical stage. Furthermore, this
system is potentially significant for various reasons: 1) it provides (and can be utilized as) a humanbased in vitro model to study disease pathophysiology (i.e., mechanisms and pathways) in vitro,
2) it provides a simple, reproduceable and economically effective tool for screening drug toxicity
and efficacy, 3) it provides a foundation for designing and creating more complex systems which
can be used to study the mechanism of drug reaction, mode of transport and to screen libraries of
already approved drugs for drug repurposing, 4) it is scalable, it can be used for low- or highthroughput drug testing, and 5) it can be used in the application of personalized medicine.

Materials and Methods
Neuronal Cells
Human cortical neurons were used in this study to assess the effects of multiple AD-related drugs
on Aβ oligomers induced neuronal cell dysfunction. The cells were derived from human induced
pluoripotent stem cells from healthy individuals and were either purchased from Cellular
Dynamics International (CDI, iCell GlutaNeurons, Cat. #: C1033, Madison,WI) or defferentiated
directly in our lab as described previously [150, 177] and Autar, et al. [151].
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Cell Culture
The cells were seeded on surfaces (MEA chips and coverslips) coated with DETA (N-1(3[trimethoxysilyl]propyl)-diethylenetriamine) followed by top coat with either poly-L-ornithine
and laminin (PLO/LM, 20 μg/ml and 10 μg/ml respectively) or fibronectin and laminin (FB/LM,
10 µg/ml each for 2 hours at RT]. A monoculture of cortical neurons were plated at a density of
150 cells/mm2 on coverslips for

immunostaining (ICC) analysis and patch-clamp

electrophysiology as decribed previously [127, 150]. For the MEA cultures, a co-culture of cortical
neurons and astrocytes were seeded directly onto patterned chips to promote cell aggregation
and/or formation of separated cell-clusters on the individual electrodes, as well as the formation
of synaptic connections between two adjacent electrodes. The neuronal cells were plated at a
density of 500 cells/mm2 and the astrocytes at 250 cells/mm2. The cells were were first plated in
the manufacture’s (CDI) recommended medium for the first 24h before they were switched to a
serum-free medium. The cells were maintained in culture in the serum-free medium for 28-35
days prior to dosing and testing [150].

Aβ Oligomer Preparation
The Aβ oligomers were prepared using peptides from rPeptide (Aβ1-42 catalog number A-1002-2;
Aβ-scrambled A-1004-2) as described previously [178]. First, the peptides were resuspended in
500µL of HFIP (catalog number AC445820100; Fisher Scientific) and left to dry overnight under
a ventilated hood. The next day the samples were spun in a SpeedVac until dry and stored
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desiccated at -20°C until use. Prior to using, the solution was sonicated for 5 minutes and
centrifuged at 1400 x g for 5 minutes.

AD Drugs
Several classes of drugs use in the treatment of Alzheimer’s disease were used in this study, including
Rolipram, Saractinib, and FDA-approved Memantine and Donepezil. Memantine is an noncompetitive
NMDA receptor antagonist that binds to the receptor and blocks the binding of glutamate and thus cell
excitotoxicity caused by glutamate [179]. Donepezil is an FDA-approved drug for AD, it is an
acetylcholinesterase inhibitor which prevents the breakdown of acetylcholine in the synapse by the
acetylcholinesterase enzyme [180, 181]. Saracatinib inhibits the action of Fyn, a member of the tyrosine
kinase family that phosphorylates other proteins including tau and NMDAR, resulting in tau
hyperphosporylation and synaptoxicity, or cell excitotoxicity from NMDAR activation [182-185]. Rolipram
is a selective phosphodiesterase-4 (PDE4) inhibitor that helps to restore cAMP levels, which is reduce) in AD
as a result of adenylate cyclase (synthesizes cAMP) inactivation by Aβ42 peptides [186].

Drug Treatment of Cortical Neurons
On the day of treatment, or at ~24hrs prior to patch recording, a half medium change was
performed, followed by the administration of either Aβscr or Aβ42 oligomers with or without AD
drugs for patch electrophysiology. Only the half medium change was performed in the systems
with the MEAs at 24 hours prior to treatment. For treatment groups, the cells were either dosed
with a final concentration of 5µM Aβscr, 5µM of Aβ1-42 alone, or 5µM of Aβ1-42 plus drug (either
10nM of Saractinib, 1µM of Donepezil, or 5µM of Memantine, 1µM of Rolipram). To examine
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the neurotoxic effects of Aβ42 oligomers on cell electrophysiological function, the cells or cultures
were tested at either 1 hour (MEAs) or 24 hours (patch-clamp) following treatment.

Immunocytochemistry and Confocal Microscopy
To analyze the cells for gene expression of the drug targets, the cells were fixed in 4%
paraformaldehyde (PFA), followed by cell permeabilization and incubation in primary and
secondary antibodies solutions (diluted in BSA/NGS/T20 buffer) for each specific marker.
Following antibodies staining, the cells were counterstained with DAPI (4’,6-diamidino-2phenylindole) and mounted on glass slides for analysis. The cells were imaged using a confocal
microscopy (Zeiss, Axioskop 2, Germany). The following primary antibodies (at 1/1000 dilution)
were used: Rabbit Anti-Microtubule-Associated Protein 2 (Millipore, Cat. #: AB5622), Mouse
Anti-MAP2 (Abcam, Cat. #:ab11257), Mouse Anti-Fyn (ThermoFisher, Cat. #: MA1-15865),
Mouse Anti-NMDAR2B (ThermoFisher, Cat. #: MA1-2014), Mouse Anti-Acetylcholinesterase
(Abcam, Cat. #: ab2803), Mouse Anti-muscarinic Acetylcholine Receptor (Abcam, Cat. #:
ab90805), Rabbit Anti-nicotinic Acetylcholine Receptor (Abcam, Cat. #: ab221868), Rabbit AntiPhosphodiesterase Type 4 (Abcam, Cat. #: ab14628). The secondary antibodies used: Alexa-Fluor
488 goat anti-rabbit (ThermoFisher, Cat. # A11008), AlexFluor 488 Goat anti-mouse
(ThermoFisher Cat. #: A11001), AlexFluor 568 Goat anti-Rabbit (ThermoFisher Cat. #: A11036),
and AlexFluor 568 Goat anti-mouse (ThermoFisher Cat. #: A11004).
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Patch Clamp Electrophysiological Recording of Cortical Neurons
Neuronal electrophysiological activity was evaluated at 28-35div. To measure cellular activity
intracellularly, whole cell patch-clamp recordings were taken using a Zeiss, upright microscope
(Axioscope, FS2, Carl Zeiss, Germany) equiped with a multiclamp 700B amplifier and an
intracellular solution consisting of 140 mM K-gluconate, 4 mM NaCl, 0.5mM CaCl2, 1mM MgCl2,
1mM EGTA, 5mM HEPES Acid, 5mM HEPES base and 5 mM Na2ATP as described previously
[150]. Depolarization-evoked inward and outward currents were examined in voltage-clamp mode
while induced action potentials (APs) were recorded in current-clamp mode. Sucessive analysis of
the data were carried out using pClamp 10 software (Axon Instrument, Foster City, CA, USA)
followed by quantification using Microsoft Excel and GraphPad Prism.

Induction of Long-Term Potentiation on MEAs
To induce LTP on cortical neurons cultured on MEAs, a high frequency stimulation (HFS)
protocol was used as described previously [150]. Test stimuli were delivered to all the electrodes
in the form of 80 pulses at 100Hz. The evoked response or induced cell activity was then analyzed
using Anaconda with Python (i.e., Monday.com) software. The waveforms (e.g., action potential
spikes and frequency) were thresholded at -5 standard deviations from the noise and high-pass
filtered at 100Hz. Any electrodes with firing frequency post-stimulation less than or equal to
baseline levels were excluded from the data analysis.

49

Analysis of Cortical Neuron Activity on MEAs
The cellular activity of the cells was measured extracellularly on MEAs as described previously
[127, 150, 187]. The cells were plated directely onto the MEA chips in housing and maintained in
culture for 28-35 days before acute treatment with Aβ oligomers and AD drugs. Prior to treatment,
spontaneous activity (baseline) of the neurons was recorded (for 5 minutes) followed immediately
by electrical stimulation (LTP induction) and another 5 minutes recording post-stimulation.
Immediately following LTP induction and recording, the cultures were treated with Aβ oligomers
and/or Aβ oligomers AD drugs and incubated for 1 hour at 37°C and 5% CO2. Next, the neuronal
firing potential (e.g., firing frequency) was once again recorded for 5 minutes before analysis. The
data was analyzed using Anaconda with Python software.

Statistical Analysis
Comparison of the mean of at least three or more replicates and more than 15 electrodes between
groups was performed. For computational analyses, Microsoft Excel software and GraphPad Prism
were used. Student t-tests were used for statistical comparison analysis between two experimental
groups, whereas one-way analysis of variance (ANOVA) with Tukey’s post hoc test was used for
multiple experimental groups. The SEM was used with statistical significance taken at p ≤ .05.
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Figures

Figure 8: Expression of gene targets of AD drugs in hiPSC-derived cortical neurons. Phase image of
hiPSC-derived cortical neurons aligning in pattern on coated MEAs at the magnification of 2.5X(A), and
10X magnification (C). Phase image of hiPSC-cortical neuron morphology on coverslips at 25X
magnification (B). (D-H) Immunocytochemistry of hiPSC-derived cortical neurons with antibodies specific
to target gene/proteins for AD drugs revealed cells expression for all markers. Scale bar = 100 m.
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Figure 9: Protective effects of AD-related drugs against Amyloid beta42 oligomers induced
neurotoxicity in cortical cells. (A-C) Patch clamp electrophysiology recordings showed a marked
reduction in sodium currents (A) in hiPSC-derived cortical neurons following 5µM Aβ42 oligomer
application at 24hrs post-treatment. Additionally, a significant decrease in both induced action potential
firing under depolarization (B) and spontaneous firing peak amplitudes (C) was detected in cells treated
with Aβ42 relative to cells dosed with amyloid beta scrambled (Aβscr), but the decrease was recovered by
co-treatment with drug. (D-F) A similar reduction in cell activity was observed in the cortical-HoAC
systems. Following establishment of baseline activity levels (D), an immediate increase in cell activity (i.e.,
firing frequency) was observed in hiPSC-derived cortical neurons following LTP induction (E). While the
induced activity was maintained at 1hr post dosing in samples treated with the amyloid beta scrambled
(Aβscr, 5µM), a sharp decrease was observed in the samples dosed with Aβ42 oligomers alone within 1hr
of treatment (F). However, co-treatment of the Aβ42 oligomers and AD drugs rescued the decrease.
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Figure 10: Amyloid beta42 oligomers induced neurotoxicity of hiPSC-derived cortical neurons is
inhibited by Donepezil. (A-D) Patch clamp electrophysiology recordings from the hiPSC-derived cortical
neurons showed the blocking of the Aβ42-induced defects by co-treatment with Donepezil (1µM) for 24
hours, as demonstrated for the readouts of sodium currents (A), action potential (AP) amplitude (B), and
spontaneous firing rate (C) and amplitude (D). (E) Analysis of cell function on cortical-MEA systems
revealed a stimulus-induced increase in cell activity (i.e., firing frequency) was maintained in control
samples dosed with amyloid beta scrambled (Aβscr, 5µM), but was completely abolished within 1h of Aβ42
oligomers dosing. However, this Aβ42-induced abolishment was blocked by co-treatment with Donepezil
(DNP, 1µM)(E). Statistical analysis was computed using either Student t-test or One-Way ANOVA with
Tukey’s test and Alpha (0.05) is significance. (N≥16), *p≤0.05, **p≤0.01, ***p ≤0.001.
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Figure 11: Figure 4. Saracatinib blocks amyloid beta42 oligomers toxic effects on hiPSC-derived
cortical neurons. (A-D) Patch clamp electrophysiology recordings from the hiPSC-derived cortical
neurons showed the blocking of the Aβ42-induced defects by co-treatment with Saracatinib (10nM) for 24
hours, as demonstrated for the readouts of Sodium currents (A), action potential (AP) amplitude (B), and
spontaneous firing rate (C) and amplitude (D). (E) Analysis of cell function on cortical-MEA systems. A
stimulus-induced increase in cell activity (i.e., firing frequency) was maintained in control samples dosed
with amyloid beta scrambled (Aβscr, 5µM), but was completely abolished within 1h of Aβ42 oligomers
dosing. However, this Aβ42-induced abolishment was blocked by co-treatment with Saracatinib (10nM).
Statistical analysis was computed using either Student t-test or One-Way ANOVA with Tukey’s test where
applicable. Alpha (0.05) is significance. (N≥25), *p≤0.05, **p≤0.01, ***p ≤0.001.
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Figure 12: Memantine suppresses amyloid beta42 oligomers neurotoxic effects on hiPSC-derived
cortical neurons. (A-D) Patch clamp electrophysiology recordings from the hiPSC-derived cortical
neurons showed the blocking of the Aβ42-induced defects by co-treatment with Memantine (5µM) for 24
hours, as demonstrated for the readouts of Sodium currents (A), action potential (AP) amplitude (B), and
spontaneous firing rate (C) and amplitude (D). (E) Analysis of cell function on cortical-MEA systems. A
stimulus-induced increase in cell activity (i.e., firing frequency) was maintained in control samples dosed
with amyloid beta scrambled (Aβscr, 5µM), but was completely abolished within 1h of Aβ42 oligomers
dosing. However, this Aβ42-induced abolishment was blocked by co-treatment with Memantine (5µM).
Statistical analysis was computed using student t-test or One-Way ANOVA with Tukey’s test and Alpha
(0.05) is significance. (N≥25), *p≤0.05, **p≤0.01, ***p ≤0.001, ****p ≤0.0001.
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Figure 13: Rolipram suppresses amyloid beta42 oligomers neurotoxic effects on hiPSC-derived
cortical neurons. (A-D) Patch clamp electrophysiology recordings from the hiPSC-derived cortical
neurons showed the blocking of the Aβ42-induced defects by co-treatment with Rolipram (1µM) for 24
hours, as demonstrated for the readouts of Sodium currents (A), action potential (AP) amplitude (B), and
spontaneous firing rate (C) and amplitude (D). (E) Analysis of cell function on cortical-MEA systems. A
stimulus-induced increase in cell activity (i.e., firing frequency) was maintained in control samples dosed
with amyloid beta scrambled (Aβscr, 5µM), but was completely abolished within 1h of Aβ42 oligomers
dosing. However, this Aβ42-induced abolishment was blocked by co-treatment with Rolipram (1µM).
Statistical analysis was computed using student t-test or One-Way ANOVA with Tukey’s test and Alpha
(0.05) is significance. (N≥18), *p≤0.05, **p≤0.01, ***p ≤0.001, **** p ≤0.0001.
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CHAPTER FOUR: VALIDATION OF SYNAPTIC CONNECTIVITYDEPENDENT LONG-TERM POTENTIATION IN A HUMAN IPSCCORTICAL NEURON MODEL FOR ASSESSING
NEURODEGENERATION
Introduction
Neurodegenerative diseases, such as frontotemporal dementia (FTD), Alzheimer’s disease
(AD), Parkinson’s disease (PD), and epilepsy are characterized by a loss of neuronal function [188191]. More specifically, deficits in motor and cognitive functions are the main symptoms that
present themselves during disease onset. In AD, the accumulation of Aβ42 oligomers form plaques
that cause synaptic deterioration and a characteristic loss of memory and learning [4]. Current
models of neurodegeneration and AD have either been in vivo models examining animal learning
and memory, including mice [192], rats [193], and non-human primates [194], or in vitro models
that employ the use of cortical neurons from rat brain slices [195] and rat dissection sources [196],
or human iPSC derived sources [39, 175]. Human iPSC cortical neurons have been commonly
utilized for studying diseases in the CNS. The utilization of a human cell source rather than an
animal cell source provides more optimized biological efficacy. When combined with in vitro
human organ-on-a-chip (HoaC) technology, they are expedient for the evaluation of neuronal
function in a biologically relevant system. There are limited in vitro models that focus on the
synaptic deterioration by evaluating synaptic plasticity in a biologically accurate manner.
Long-term potentiation (LTP) has been used both in vivo and in vitro as a means of
assessing synaptic strength, and its maintenance has been largely used as an in vitro, quantitative
readout of cognitive functions such as memory and learning. LTP has been widely studied as a
dual-patch clamp readout, with few studies looking at LTP as a readout of synaptic connectivity
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of neuronal populations on MEAs. Some studies have evaluated connectivity on MEAs of neuronal
populations seeded on a bed of electrodes in a randomized assortment [39, 175]. However, when
the neurons are arranged in a disorganized fashion, changes in neuronal activity resulting from
synaptic communication cannot be well tracked and defined within the system. That being said, it
has been previously shown that surface chemistry patterning allows for organized cell culture
[125]. By combining surface patterning with HoaC technology on MEAs, a tool can be created for
more optimized assessment of synaptic plasticity.
This study sought to validate a system for studying synapse-dependent neurodegeneration
by developing a model of LTP induction via synaptic connectivity. We evaluated the
communication between patterned neuronal populations, where the synapses were organized
between two distinct populations on individual electrodes. Although other papers have cited LTP
induction on MEAs with the employment of a serum-free, hiPSC-cortical neuron and astrocyte coculture, none have been able to induce the LTP through synaptic connectivity in a paired-patterned
fashion. By emphasizing synaptic strength as the only means for attaining LTP, this system is more
advantageous in evaluating neurodegeneration, and can be further adapted for evaluating drug
effects in a human-based system as a platform for preclinical compound assessment.

Results
Culture Timeline and Testing Procedure
Astrocytes were pre-cultured for expansion 3 days prior to iPSC-cortical neuron thawing and
plating. Following seeding of the co-culture, MEAs were maintained for at least 40 days prior to
experimentation (Figure 14A). For MEA testing, spontaneous neuronal activity was first recorded
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to establish a baseline and determine channels of interest. Next, the electrodes paired to the
channels of interest were electrically stimulated using HFS to evaluate the ability of the neurons
to experienced elevated firing levels (induced LTP). The channels of interest were then stimulated
for further assessment. A dosage of 1mM lidocaine was added following all testing in each
experiment to confirm biological signals (Figure 14B).

Characterization of Co-Culture and Confirmation of Neuronal Signals on cMEAs
Neuronal paired-electrode patterning could be visualized via phase microscopy. Representative
phase images demonstrate the patterning abilities and morphology of the co-culture at 45 DIV
(Figure 15A). Immunocytochemical staining of the MEA co-culture illustrates the neuronal and
astrocyte components using MAP2 and GFAP, respectively (Figure 15B). Neuronal signals were
confirmed as biological with the addition of lidocaine to the MEAs following recording of
spontaneous activity. Waveform representations and raster plots exemplify the abolishment of
neuronal signals after 1-minute of lidocaine addition (Figure 15C). A quantitative representation
of this abolishment shows that the change is very significant, with the signals being almost nonexistent in the presence of lidocaine (Figure 15D).

Induction of LTP via Synaptic Connectivity
Synapse formation in cortical neuron culture was first visualized for confirmation via
immunocytochemical staining. Synaptic puncta illustrated the presence of post-synaptic densities
(PSD95) as well as synaptophysin pre-synaptic synaptic vesicles (Figure 16A). Next, electrodes
of interest were determined as either the top row or bottom row electrodes, synaptically connected
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through neuronal patterning. Electrical stimulation via a high frequency stimulation (HFS)
protocol was first performed on the adjoining electrodes to synaptically stimulate the electrodes of
interest. Waveform traces and corresponding raster plots reveal that neuronal activity increased in
the electrodes of interest increased following stimulation of the paired electrode, while it did not
in the non-stimulated control (Figure 16B). Quantification of the neuronal firing rate revealed the
induction of heightened activity on the electrode of interest following the stimulation of the paired
channel was significantly higher than the baseline (Figure 16C). However, when the channel of
interest was stimulated proceeding stimulation of the paired channel, there was no notable increase
compared to the previous stimulation. No significant change was observed in non-stimulated
controls, emphasizing that any changes in neuronal activity were a response to electrical
stimulation. It was also found that the induced increase following HFS in the channels that were
stimulated via their synaptic connections was not significantly different than the increase in the
electrodes that were directly stimulated (Figure 16D).

Confirmation of Synaptic LTP Through AMPA Receptor Inhibition
The presence of AMPA receptors on the surface of iPSC-cortical neurons was visualized via
immunocytochemical staining for the AMPA receptor subunit GLUR1, co-stained with
synaptophysin for further synapse confirmation (Figure 17A). Following recording of baseline
neuronal activity levels, AMPA receptors were blocked through the addition of NBQX or 0.1%
DMSO vehicle control. Next, stimulation was performed as mentioned in Figure 3, with the paired
channels stimulated first, followed immediately by the stimulation of the channels of interest. LTP
was then evaluated by recording the spontaneous neuronal activity again 1 hour following the HFS
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stimulation protocol. The results revealed a significant decrease in the induction and maintenance
of LTP in the presence of NBQX (Figure 17B). Waveform traces and raster plots further
demonstrate this difference (Figure 17C).

Confirmation of Synaptic LTP through NMDA Receptor Inhibition
The presence of NMDA receptors in our cortical neuron culture was first assessed via
immunocytochemical staining using an NMDAR antibody. MEAs were co-stained with vGLUT1
to confirm the excitatory character of our neurons through the release of vesicular glutamate as a
neurotransmitter (Figure 18A). The addition of D-AP5 to inhibit NMDA receptors significantly
blocked the induction and maintenance of LTP through synaptic connectivity compared to vehicle
control (Figure 18B). Waveform traces and raster plots further illustrate the differences observed
in neuronal activity on MEAs (Figure 18C).

Discussion
This study sought to evaluate LTP from a high-frequency electrical stimulation,
synaptically-induced change in paired neuronal populations. Current models of LTP analyze the
results of direct stimulation, but the utilization of synaptically-induced LTP enables for a more
robust system for investigating neurodegeneration as a result of synaptic decline. Models of
synaptic plasticity in Alzheimer’s disease commonly employ a tetanic high-frequency stimulation
protocol, and subsequently measure the slops of the excitatory post-synaptic potential (EPSP).
Recently, the use of MEAs has encouraged the exploration of neuronal population dynamics and
network integrity [128, 197, 198].
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A cortical neuron and astrocyte co-culture was used for the evaluation of LTP induced
through synaptic connectivity of distinct neuronal populations on MEAs. The cortical neuron and
astrocyte co-culture was seeded according to the culture timeline depicted in Figure 14A, where
astrocytes were first expanded prior to co-seeding of cortical neurons and astrocytes. The coculture was allowed to pattern and form strong synaptic networks between the neuronal
populations for 40-50 days following cell seeding prior to evaluation of neuronal activity. This
timeline has been previously validated as a mature cortical neuron time window [151]. The
utilization of paired neuronal patterning on MEA chips allowed for distinct neuronal populations
to form with guided synaptic networking for controlled stimulation and neural communication.
The LTP protocol detailed in Figure 14B sought to investigate the differences in electrical
stimulation from the synaptically connected neuronal population compared to the direct
stimulation of the neuronal population localized on a given electrode. This technique has been
used previously to evaluate synaptic connectivity between differing neuronal populations to
evaluate the communication via the release of different neurotransmitters [199].
Photolithographic patterning allowed for the successful formation of paired neuronal
populations visualized through phase microscopy (Figure 15A). Cortical neuron and astrocyte cocultures have been widely used in vitro for the investigation of synaptic plasticity and LTP [175,
200-202]. The utilization of astrocytes within the neuronal culture aids in the synaptic strength and
axonal robustness within the culture as well as culture duration [203]. Staining of MEA chips
allowed for visualization of the neuron and astrocyte co-culture using MAP2 and GFAP,
respectively (Figure 15B), illustrating the integration of the astrocytes within the neuronal
population, which is imperative for glutamate recycling within the synaptic cleft. Lidocaine, a
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widely cited local anesthetic, was used for confirmation of biological neuronal signals by blocking
Na+ channels and were shown to abolish neuronal signals within 1 minute following administration
(Figure 15C and 15D) [151].
Following the characterization of the astrocyte and neuronal culture and confirmation of
biological signals, high frequency electrical stimulation (HFS) was employed following the
protocol described in Figure 14B. Synaptic connectivity between neurons was visualized through
immunocytochemical staining of synaptic puncta using PSD95 and Synaptophysin (Figure 16A).
Following this, the LTP induction was performed according to the protocol in Figure 15B. Similar
levels of neuronal activity were present in stimulated and non-stimulated neuronal populations
(Figure 16B). A significant increase was observed in neurons stimulated through synaptic
networking when the connected electrode was stimulated, however, the neurons could not be
further stimulated through the subsequent direct stimulation (Figure 16C). Additionally, the
increase in neuronal activity when stimulation occurred through synaptic stimulation of the
opposite electrode was not significantly different than the increase observed from the direct
stimulation of the neurons, indicating that the LTP induction is statistically equivalent when
stimulated through the neuronal synaptic networks (Figure 16D). While previous works have
investigated the LTP phenomenon on MEAs, they have not looked specifically at the induction of
LTP through synaptic connectivity, but rather through trained test-pulses on the neuronal
population localized on the same electrode [39].
For further validation, AMPA and NMDA receptors were blocked to affirm that the LTP
induction from adjacent, connected neuronal population was occurring through the synaptic
networks. It has been cited that LTP is NMDA-dependent, due to the fact that NMDA receptors
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are voltage-dependent [45]. AMPA receptors were visualized using GLUR1, with Synaptophysin
used as a comparative stain to fully visualize the synaptic networks (Figure 17A). AMPA receptors
were blocked using a potent AMPA receptor antagonist, NBQX [204]. Baseline activity was taken
prior to dosing with NBQX, where a notable, though non-significant, decrease in neuronal activity
was observed. In comparison to the 0.01% DMSO control, where LTP was induced synaptically,
there was a significant difference in the LTP induction in the NBQX dosed systems. This
difference was also observed 1 hour following induction, where the control systems maintained
their elevated firing, and the cultures dosed with NBQX did not experience any long-term effects
following stimulation (Figures 17B and 16C). This indicates that the notable increases in neuronal
activity are from synaptic stimulation. Similar results were attained when neuronal NMDA
receptors were blocked with D-AP5, which has been correlated to blocking LTP capabilities [205].
NMDA receptors were first visualized using an NMDAR antibody co-stained with vGLUT1 for
complete depiction of the synaptic connections (Figure 18A). Because NMDA receptors are only
activated following depolarization of the membrane to a threshold voltage, there was less of an
observed decrease in neuronal activity following the administration of the compound. However,
when compared to the vehicle control, the lack of induced and persistent LTP immediately
following and 1 hour after stimulation was significantly different (Figure 18B and 18C). Therefore,
the blocking of the post-synaptic receptors activated by glutamate released from pre-synaptic
vesicles also blocked the synaptic induction of LTP [206].
The validation of a functional, in vitro LTP model that emphasizes the synaptic integrity
allows for further advancements in neurodegenerative diseases, such as AD, that is hallmarked by
synaptic decline. Furthermore, because the populations have an isolated locality, other cell types

64

can be integrated into this system to look at networking of many types of neurons present within
the brain. Combining this system with iPSC technology provides a platform for patient-specific
disease models of neurodegeneration, and the utilization of a fully human-based, in vitro system
easily lends itself to surveying drug efficacy in precision medicine.

Materials and Methods
MEA Patterning and Surface Prep
MEAs were first coated with poly-ethylene glycol (PEG) as per [207]. Next, the PEG-coating was
ablated using a laser using a mask that formed the paired pattern, where the neuronal populations
were localized on the electrode tips, and axonal tracks were present to connect and pair the
populations. Following laser ablation, the surfaces were backfilled with a DETA coating to
encourage neuronal binding to the patterns. The surfaces were then coated with a solution of
10g/mL Fibronectin (Sigma-Aldrich #F1141) and Laminin (Invitrogen #23017-015), diluted in
1X PBS. The laminin solution was cured at RT for 3 hours preceding the seeding of the cortical
neuron and astrocyte co-culture.

Cell Culture
Primary astrocytes were pre-cultured for 3 days in a T-75 flask using a vendor media formulation
(ScienCell Human AM #1801) before being co-cultured with cortical neurons. At culture D0,
astrocytes were lifted using accutase (Sigma Aldrich #A6964) at 37C following a 1X PBS rinse.
Astrocytes were then centrifuged at 300g for 4 minutes. iPSC-cortical neurons (iCell
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Glutaneurons) were purchased from CDI (Cellular Dynamics #R1116) and thawed following
vendor specifications in CDI media, consisting of BrainPhys Neuronal Media (Stemcell
Technologies #05790) supplemented with Nervous System Supplement (Cellular Dynamics
#M1031), Neural Supplement B (Cellular Dynamics #M1029), 1X N2 Supplement (ThermoFisher
17502048), 1g/mL Laminin (Invitrogen #23017-015), and 1X Pen/Step (15-ThermoFisher 140122). Cells were seeded at a 2:1 neuron-to-astrocyte ratio, with neurons seeded at 500cells/mm2
and astrocytes seeded at 250cells/mm2 on cMEAs. One day following seeding, a full media change
was performed on the cultures to switch them to NMJ medium. A half-media change was
performed every other day for the duration of the culture. Full-media washouts were performed
after testing to remove added compounds.

Immunocytochemistry
Coverslips were fixed and permeabilized as previously published [151]. Following
permeabilization, coverslips were blocked in blocking solution containing 1% BSA and 5% goat
serum in 1X PBS. Primary antibodies were diluted in blocking solution and incubated at 4°C
overnight. Antibodies used for visualization included Rabbit-anti-GFAP (Sigma ab5804, 1:1000),
Mouse-anti-MAP2 (Invitrogen MA5-12823, 1:500), Mouse-anti-Synaptophysin, Rabbit-antiPSD95, Guinea Pig-anti-vGLUT1 (Invitrogen ab5905, 1:200), Rabbit-anti-GLUR1 (Invitrogen
ab1504, 1:250), and Mouse-anti-NMDAR (Invitrogen MA1-2014, 1:250). Secondary antibodies
used included: Goat anti-Rabbit Secondary Antibody Alexa Fluor 568 (ThermoFisher A-11011),
Goat anti-Mouse Secondary Antibody Alexa Fluor 568 (ThermoFisher A-11004), Goat antiRabbit Secondary Antibody Alexa Fluor 488 (ThermoFisher A11008), Goat anti-Mouse
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Secondary Antibody Alexa Fluor 488 (ThermoFisher A-11001). Coverslips were additionally
counterstained with DAPI (Fisher D1306) for nuclear visualization (1:500) and mounted using
Invitrogen DAPI mounting media (Fischer P36931).

Compound Preparation
All compounds were prepared as a stock such that the concentration was 100X final dosing
concentration and could be dosed as 8L in a total system volume of 800L. Lidocaine HCl
(Sigma 6108-05-0) was reconstituted in cell culture media at a concentration of 100mM, final
concentration 1mM. NBQX (TOCRIS 0373) was reconstituted in 0.1% DMSO diluted in cell
culture media and dosed at a final concentration of 25M. D-AP5 (TOCRIS 0106) was
reconstituted in cell culture media and dosed at a final concentration of 25M.

LTP Induction and Analysis
MEA recordings were taken using a multi-channel systems rig (MCS). Electrical stimulation was
performed using a high-frequency stimulation (HFS) LTP induction protocol that has been
previously used in our other works. All recordings of neuronal activity were taken for a duration
of 5 minutes. Raw data was processed with a 100Hz high-pass 2nd order Butterworth filter. In
addition, a -5 standard deviation threshold was used for event detection. Events crossing the
threshold were further filtered using a principal component analysis (PCA) filter.
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Figures

Figure 14: Culture timeline and testing procedure. (A) Culture timeline illustration of co-culture plating,
where astrocytes were pre-plated and expanded in T-75 flask 3 days prior to lifting and co-seeding with
cortical neurons. Experimentation was performed 45-55 days following cell seeding. (B) Illustration
depicting testing procedure, where baseline activity was recorded. HFS was performed on electrodes
opposite of visibly active electrodes. Then the opposite row was stimulated. Last, lidocaine was
administered for confirmation of biological activity. All recordings were taken for a duration of 5 minutes.
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Figure 15: Co-culture characterization and confirmation of neuronal activity. (A) Phase images
depicting patterning of neuronal population on cMEA chips using 2.5X (left), 10X (middle), and 25X (right)
objective lenses (Scale Bar = 100m). (B) Immunocytochemistry staining of hiPSC-cortical neuron and
astrocyte co-culture depicting neurons (MAP2, green), astrocytes (GFAP, red) and nuclear counterstain
(DAPI, blue) utilizing 40X objective confocal microscopy (Scale Bar = 50 m). (C) Representative
waveform illustrations and accompanying raster plots of neuronal frequency in a 5-minute baseline
recording (left) and 1 minute following addition of 1mM lidocaine (right). (D) Graphical representation of
neuronal firing frequencies at baseline and 1-minute following addition of lidocaine from 3 independent
experiments. Statistical analysis was performed using a Student’s t-test, *p < 0.05, **p < 0.01, ***p <
0.001.
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Figure 16: Evaluation of synaptic connectivity via LTP induction. (A) Immunocytochemical staining
for visualization of synaptic connectivity using PSD95 (green), Synaptophysin (red) and nuclear
counterstained with DAPI (blue) using confocal imaging 40X objective (Scale Bar = 50 m). (B)
Representative waveform traces and accompanying raster plots for neuronal baseline activity, stimulation
of opposing electrodes, and stimulation of active electrodes for stimulated systems and non-stimulated
controls, confirming that neuronal activity does not change without stimulation. (C) Graphical
representation of stimulated and non-stimulated systems, where a significant change in activity was not
observed in non-stimulated systems, but a significant increase in neuronal activity was observed in active
channels when the opposing channel was stimulated. (D) Graphical comparison of increased neuronal
activity following direct HFS of the active electrode and indirect HFS (stimulation of the opposite electrode)
of the active electrode, concluding that the increases in activity are not statistically different. Statistical
analysis was determined via One-Way ANOVA and post-hoc analysis via Tukey’s HSD and Student’s ttest, *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 17: Figure 4: Validation of LTP induction and maintenance through addition of NBQX. (A)
Immunocytochemical staining for confirmation of AMPA receptor presence using Synaptophysin (green),
AMPA receptor subunit GLUR1 (red) and nuclear counterstained with DAPI (blue) using confocal imaging
40X objective (Scale Bar = 50m). (B) Graphical representation of LTP induction and maintenance via
HFS in the presence of AMPA receptor antagonist NBQX and vehicle control 0.01% DMSO, where LTP
could be induced and maintained for 1 hour in vehicle control systems but could not in the presence of
NBQX. (C) Representative waveform traces and accompanying raster plots for neuronal baseline activity,
following the addition of NBQX, and following HFS and LTP maintenance at 1-hour post-stimulation.
Statistical analysis was determined via One-Way ANOVA and post-hoc analysis via Tukey’s HSD and
Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 18: Validation of LTP induction and maintenance through addition of D-AP5. (A)
Immunocytochemical staining for confirmation of NMDA receptor presence using NMDAR (green),
vesicular glutamate antibody vGLUT1 for visualization of the presence of the neurotransmitter glutamate
(red) and nuclear counterstained with DAPI (blue) using confocal imaging 40X objective (Scale Bar =
50m). (B) Graphical representation of LTP induction and maintenance via HFS in the presence of NMDA
receptor antagonist D-AP5 and vehicle control, where LTP could be induced and maintained for 1 hour in
vehicle control systems but could not in the presence of D-AP5. (C) Representative waveform traces and
accompanying raster plots for neuronal baseline activity, following the addition of D-AP5, and following
HFS and LTP maintenance at 1-hour post-stimulation. Statistical analysis was determined via One-Way
ANOVA and post-hoc analysis via Tukey’s HSD and Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001.
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CHAPTER FIVE: EVALUATION OF LONG-TERM POTENTIATION IN
AN IPSC-CORTICAL NEURON MODEL OF FAMILIAL ALZHEIMER’S
DISEASE
Introduction
Alzheimer’s disease (AD) is a neurodegenerative disease defined pathologically as the
deterioration of synaptic networks attributing to the cognitive functions of memory and learning
[208]. The main hypothesis for the mechanism of neurodegeneration in AD is through the
accumulation of neurotoxic Aβ42 plaques and/or tau neurofibrillary tangles, the latter of which
may be dependent on the pathology of the former [209]. The formation of Aβ42 plaques is further
hypothesized to non-specifically bind to post-synaptic receptors when released from the presynaptic neuron to trigger excitotoxity [210] and inflammation [211] among other detrimental
effects. There is much speculation regarding the source of the Aβ42 plaques, the most explored of
which is from familial AD (FAD) mutations.
AD is theorized to be caused by the accumulation of Aβ42 oligomers following the
neurotoxic elongation caused by improper cleavage of amyloid precursor protein (APP) into the
non-pathologic Aβ40 oligomer [4]. The cleavage of APP to Aβ40 is the responsibility of the
gamma secretase complex, which is comprised of four main components: presenilins 1 and 2
(PSEN1 and PSEN2), nicastrin, anterior pharynx defective 1 (APH-1), and presenilin enhancer 2
(PEN-2) [212]. The presenilin genes encode for the PSEN1 and PSEN2 subunits, which are the
main catalytic components of the complex. Missense mutations in these genes can lead to
dysfunction of the catalytic proficiency of the gamma secretase complex [213, 214]. Notably,
mutations in the PSEN1 vs. the PSEN2 gene can cause dramatically different downstream effects,
due to being shuttled to differing subcellular locations [215].
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The PSEN1 gene is the main catalytic subunit of the gamma secretase complex [216].
When it harbors an FAD mutation, it tends to have increased neurogenesis, leading to the
spontaneous differentiation of iPSCs [217, 218]. PSEN1 subsequently gets shuttled to the plasma
membrane, generating the predominant extracellular pool of Aβ42 oligomers, which then
accumulate into plaques within the synaptic cleft and cause the detrimental deterioration of neural
networks [219]. Mutations in the PSEN1 gene are most heavily linked to the excitotoxicity
hypothesis, which claims that Aβ42 plaques interfere with proper glutamate reuptake, leading to
hyperexcitability preceding excitotoxicity-mediated synaptic deterioration and neuronal cell death
[83, 220, 221].
In contrast, the PSEN2 subunit becomes localized within the cell’s endosomes and
lysosomes to generate intracellular Aβ peptides [215, 222]. It has been speculated that a PSEN2
subunit derived from an FAD mutated gene may increase the activity of the gamma secretase
subunit, leading to a heightened generation of Aβ42 oligomers [223]. The presence of excessive
pathological Aβ42 intracellularly potentially leads to premature neuronal maturation
encompassing the rapid depletion of the neural progenitor population and cellular apoptosis [224226].
Apolipoprotein E4 (ApoE4) is a gene variant that has been linked to a genetic
predisposition for the development of AD. It is mainly expressed in the blood-brain barrier (BBB)
and liver [227]. The physiological function of ApoE is the metabolism of fat by processing lipids
to form lipoproteins responsible for cholesterol transport [228]. While there are several variants,
(E2, E3, and E4,) E3 being the most widely expressed, the E4 variant has been associated with an
increased genetic risk for developing AD due to its hypolipidation [227]. The mechanism of action
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of AD onset from ApoE4 suggests that E4 causes Aβ accumulation through improper clearance
[32, 229, 230] and dysfunction in lipid metabolism within the brain [231, 232]. This lipid
dysfunction is thought to be primarily contributed by astrocytes in the BBB, which promote
increased APP and subsequently the generated pool of Aβ [233]. It has also been cited that the
possession of the ApoE4 gene leads to accelerated neuronal maturation and rapid depletion of the
neural progenitor pool throughout development, clinically linked to premature aging, due to a
characteristic lack of cholesterol binding affecting the neuronal maturation cycle [234, 235].
Several in vivo knock-out and knock-in mouse models have evaluated the neuronal
function and neural population dynamics with and without FAD mutations for the designated genes
[236-238]. While there have also been several in vitro studies examining neuronal function and
analyzing the effects on neuronal function, few have looked at human-derived neurons from FAD
iPSCs, and even less have been able to evaluate synaptic plasticity in a quantifiable, in vitro assay
for cognition and memory: LTP. This study aimed to characterize the differentiation of human
iPSC-cortical neurons from multiple, pre-established FAD iPSC lines. Following the
differentiation, neuronal activity and LTP capabilities will be evaluated to establish a mechanism
of AD onset and neurodegeneration. Developing functional, in vitro systems for the assessment of
neurodegeneration in FAD provides a tool for surveying the potency of drug treatments and
preclinical AD therapeutics.

75

Results
Characterization of Accelerated Maturation and Apoptosis in Mutant Lines
One notable result following the differentiation of AD cortical neurons was the distinct behavior
of each line throughout maturation (Figure 19). It was discovered that the PSEN1 line experienced
heightened proliferation and enhanced Nestin character compared to our WT control. In contrast,
the PSEN2 and ApoE4 lines, both cited as possessing accelerated maturation phenotypes, had less
Nestin expression and significantly increased cellular apoptosis detected by Cell Titer Glo
Luminescence Assay by 14 DIV. Consequently, subsequent cell seedings were performed at higher
plating densities to counteract neuronal apoptosis and encourage culture preservation to 28 DIV.

Characterization of Cortical Neurons
Following differentiation, cortical neuron character was determined via immunocytochemical
staining with ctip2. This layer V cortical neuron transcription factor has been previously shown in
literature as a marker for confirming the successful differentiation of cortical neurons [66, 151].
All differentiated lines expressed ctip2 at 28 DIV (Figure 20). For enhanced visualization of
neuronal morphology, neurons were co-stained with MAP2, which is distinct to mature cortical
neurons [239]. Excitatory character confirmation and synaptic puncta visualization was achieved
through staining with vGLUT1, which was co-stained for the expression of AMPA receptor
subunit GLUR1, a common post-synaptic marker (Figure 21).
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Characterization of Cortical Neurons Via Whole-Cell Patch Clamp Electrophysiology
Whole-cell patch clamp recordings revealed an accelerated maturation phenotype in AD mutant
PSEN1 and PSEN2 cortical neurons, which was not significantly obvious in ApoE4 cortical
neurons compared to our WT control (Figure 22). Gap-free recordings of spontaneous neuronal
activity illustrated hyperexcitation in PSEN1 cortical neurons at 14 and 21 DIV, and a significant
decline in neuronal activity at 28 DIV, all of which were statistically significant from WT control
cortical neurons. Firing rates of PSEN2 cortical neurons were only significantly higher than WT
cortical neurons at D21, while ApoE4 cortical neurons were not significantly different than WT
control neurons. Similarly, induced repetitive firing of PSEN1 cortical neurons were significantly
higher than WT control on D14 and D21, and significantly lower on D28 (Figure 23), indicating
hyperexcitability at the earlier timepoints and neuronal decline through excitotoxicity at D28,
when the WT neurons were functionally mature. PSEN1 cortical neurons did not exhibit
significantly higher firing rates on D14 and D21, but did have a significantly lower firing rate on
D28. Unlike the spontaneous firing of ApoE4 cortical neurons, the induced repetitive firing was
significantly higher than WT control cortical neurons at D28. This trend was correspondingly
reflected in the sodium current measurements at each timepoint (Figure 24). While none of the
evaluated lines showed a significant difference when compared to the WT control on D21, the
PSEN1 and PSEN2 cortical neurons currents were both significantly higher than WT on D14 and
significantly lower than WT on D28. These readings illustrate that the PSEN1 line possesses the
most dramatic difference from our WT control line, with the PSEN2 line following a similar trend,
and the ApoE4 line being the least different when characterized for phenotypic changes on an
individual neuron level.
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Evaluation of Long-Term Potentiation in WT and AD Cortical Neurons
The evaluation of long-term potentiation on MEAs enables for the assessment of the synaptic
integrity of neuronal networks overtime. LTP maintenance for each line was consistent with
neuronal firing trends from whole-cell patch clamp recordings. At D21, it was observed that LTP
was achieved at 1-hour in the PSEN1, PSEN2, and ApoE4 lines, but was not displayed in WT
control cortical neuron cultures (Figure 25). Previous data has concluded that WT control neurons
reach functional maturation at D28, which was reflected in D28 LTP recordings (Figure 26). LTP
was observed at 1-hour recordings in the WT control cortical neurons, but was not achieved in the
PSEN1, PSEN2, and ApoE4 lines, confirming the synaptic decline within this timepoint akin to
AD onset.

Discussion
Although AD has been widely studied, many models of FAD have either employed ratbased in vivo or in vitro models with knock-in AD mutations or have lacked the functional basis
for analyzing LTP at the synaptic level [236-238, 240]. By integrating a human-derived, mature
iPSC-cortical neuron model with a system capable of assessing neuronal connectivity, we have
been able to evaluate LTP in FAD-derived cortical neurons as a function of synaptic integrity and
monitor the neuronal behavior and network degradation overtime. This study has demonstrated
that our iPSC-cortical neuron differentiation protocol can be adapted to develop patient-specific
disease models for assessing cognitive dysfunction in vitro.
Following iPSC expansion and neuronal differentiation, immediate differences were noted
between the AD lines and our WT control. The differences in the exhibition of neuroprogenitor
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and mature neuronal character in the cultures following characterization has been cited in literature
as specific to each mutation. The PSEN1 mutation has been noted to possess heightened
neurogenesis, meaning iPSCs carrying this mutation tend to self-differentiate into neurons and
glial cells [241]. While glial cells were present in our PSEN1 cultures, we still observed a
substantial amount of ctip2 positive cortical neurons that co-expressed MAP2. In contrast, the
PSEN2 and ApoE4 AD lines have both been cited as having an accelerated maturation profile,
where the neuroprogenitor pool was depleted compared to WT control neurons, and neurons
experienced expedient maturation and culture decline. As a result, these lines were plated at a
higher plating density to compensate for density loss and encourage culture preservation.
The PSEN1 mutation has been widely hypothesized to follow the excitotoxicity theory for
AD onset, which states that hyperexcitation due to improper glutamate reuptake from the presence
of Aβ42 in the synaptic cleft precedes synaptic deterioration from excitotoxicity [83, 220, 242].
Our findings support this hypothesis, as whole cell patch clamp results illustrate a premature
hyperexcitation of the PSEN1 cortical neurons in the spontaneous and induced repetitive firing
readouts at 14 and 21 DIV, which then decline rapidly within the time window of the maturation
of the WT control cortical neurons. While other literature sources have cited hyperexcitation of
the PSEN1 mutation [28, 214, 217] evident through whole-cell patch clamp recordings [83], they
did not evaluate LTP or other neuronal population dynamics.
Neurons were cultures on MEAs to evaluate differences in LTP proficiency overtime.
MEA recordings of 1hr LTP persistence demonstrate that, while the PSEN1 neuronal population
did show induced LTP following HFS, it could only maintain LTP at 14 DIV, with 21 and 28 DIV
showing a graded decrease in activity 1 hour following stimulation (Figures 25-26). Other
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literature sources charactering PSEN1 iPSC-cortical neurons have illustrated hyperexcitation at
earlier timepoints compared to isogenic WT controls through whole cell patch clamp recordings,
showing a significant increase in sodium currents as well as induced and spontaneous neuronal
firing [83, 243]. This is consistent with clinical claims that patients possessing a PSEN1 mutations
exhibit hyperexcitation symptoms in the form of epileptic seizures in their early adult years (20s30s), which precedes the deterioration of neural networks and cognitive decline [27, 28].
The PSEN2 mutations differs from PSEN1 in that it is theorized to generate an intracellular
pool of Aβ42 as opposed to amassing extracellular oligomers [215, 244, 245]. As a result, it is
hypothesized that the effect of the PSEN2 mutation on AD onset would be less severe because it
would not have a direct effect on the extracellular synaptic deterioration, but more likely
implicated in Ca+2 homeostasis [246]. While our results show that the PSEN2 mutation performed
similarly to the PSEN1 mutations in patch clamp electrophysiology recordings, the results were
less significant in comparison to our WT control. This result was also depicted in the 1-hour LTP
maintenance recordings, where we were able to achieve LTP at 21 DIV, but we did not observe
persistent LTP at 28 DIV, where the WT control cortical neuron population exhibits LTP
capabilities.
Although our ApoE4 line showed accelerated maturation and premature apoptosis, we
were able to preserve the culture to assess functional activity and LTP up to 28 DIV by increasing
the seeding density. ApoE is responsible for cholesterol transport by the formation of lipoproteins,
but ApoE4 is hypolipidated, meaning it possesses lower cholesterol transport capabilities [247].
This has been shown to contribute to improper neuronal maturation and excessive cellular
apoptosis [234], which is reflected in our culture conditions, as illustrated through a lower
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expression of the neuroprogenitor marker Nestin and cell viability assays. The onset of AD through
the ApoE4 gene is postulated to be due to the agglomeration of Aβ to form plaques through
improper clearance mechanisms [230, 248, 249]. However, this was not shown to have marked
effects on neuronal electrophysiological properties, as the ApoE4 cortical neurons did not perform
significantly differently than the WT control cortical neurons, except with a slightly heightened
induced firing frequency at 21 DIV that was found to be significant. Like the PSEN1 and PSEN2
lines, the ApoE4 cortical neuron population was able to maintain persistent LTP at 1-hour at 21
DIV. However, MEA recordings confirmed synaptic decline at the timepoint of WT control
maturation and LTP assessment, as we were unable to achieve LTP at 28 DIV.
Overall, our previously established protocol for the differentiation of iPSC-cortical neurons
for the evaluation of LTP on MEAs has been shown to be adaptable to patient-derived lines for
assessing cognitive decline in CNS diseases, such as AD, as illustrated in this study. Our findings
support literature hypothesis on common FAD mutations of the PSEN1 and PSEN2 subunits
affecting the cleavage of Aβ, where we observed significant premature hyperexcitation that was
translatable from patch clamp recordings to LTP persistence. The functional assessment was
extended to the ApoE4 genetic predisposition for AD, where we could not achieve LTP within the
normal maturation window of our WT control cortical neurons. By integrating the use of patientderived AD iPSC-cortical neurons with our in vitro system for the functional evaluation of synaptic
integrity, we have provided a platform that can be further expounded upon for the assessment of
drug efficacy in the prevention and treatment of AD in precision medicine.
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Materials and Methods
Cell Lines and iPSC Expansion
WT control iPSCs (ND41865) were purchased from the Coriell Institute. Patient-derived iPSCs
for the PSEN1 (CS40iFAD) and PSEN2 (CS08iFAD) AD mutations were purchased from Cedars
Sinai. The ApoE4/4 line was purchased from Bioneer (BIONi010-C-4) and was expanded
according to manufacturer specifications prior to adopting the standard protocol listed in these
methods. Surfaces used for iPSC expansion were 1g Corning Matrigel (Fisher CB-40230) diluted
in DMEM F-12 without phenol red (Fisher 21-041-025). Matrigel was deposited onto the surface
and allowed to equilibrate for 1 hour at RT and aspirated prior to cell seeding. iPSCs were
maintained in mTESR1 Basal Media (Stemcell 85850) that was supplemented with 5M Y-27632
(Stemcell 72304) for the first 24 hours following iPSC thawing and passaging with Relesr
(Stemcell 05872). A full medium exchange was performed each day throughout culture
maintenance. Following the initial thawing, iPSCs were passaged at 70% confluency for expansion
and differentiated after at least five passages at 90% cell confluency.

iPSC-Cortical Neuron Differentiation
Cortical neuron differentiation was initiated at 90% iPSC confluency. A full medium exchange
was performed every other day throughout differentiation. Differentiation medium I was used for
the first 4 days to induce neuroepithelial character, which was composed of a base of N2B media
(Table 1), with the addition of Differentiation medium I factors outlined in Table 2. Following
neuroepithelial induction, the neurons were directed into the rostral neuroepithelial lineage through
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differentiation medium II (Table 3). Lastly, a neurobasal-based cortical neuron media was used
for 10 days before neuronal harvesting to establish cortical neuron character (Table 4).

Cortical Neuron Plating and Maintenance
Cortical neurons were harvested following differentiation using 1X trypsin (Fisher 15-400-054)
incubated for 5 minutes at 37°C followed by trypsin inhibitor (Fisher 17075029). Once the cell
suspension was collected, cells were centrifuged at 260g for 3 minutes. Cell stocks were frozen in
a 10% DMSO (Sigma D4540-100ml) solution of cortical neuron maintenance media (Table 4).
Following harvesting or thawing using the drop-by-drop methods with cold 1X PBS, cortical
neurons were maintained for 7 days in maintenance media (Table 4) with half-medium exchanges
twice weekly. After day 7, the half-medium exchanges were performed using BrainPhys media
(Table 5) for the duration of the culture. Viability assessments were performed using Cell Titer
Glo Luminescence Cell Viability Assay (Fisher G7571). Staurosporine (Sigma 19-123MG) was
used at a concentration of 1mM incubated at 37°C for 24h in the cell culture as a negative control
for cell viability.

Immunocytochemistry
Cells intended for immunocytochemical analysis were seeded onto 18mm glass coverslips coated
with DETA [250]. Cells were fixed for 15 mins at RT using a 4% paraformaldehyde solution (16%,
ThermoFisher 28908) diluted in 1X PBS. Coverslips were rinsed thrice following fixing, and
permeabilized for intracellular stains for 15 mins at RT using 0.1% Triton X-100 (Sigma 9036-195). Non-specific binding sites were then blocked in a blocking solution of 5% BSA (Cayman
83

Chemicals A23016) and 5% goat serum (Sigma S26-100 ml) diluted in 1X PBS for 1hr at RT.
Primary antibodies were diluted in blocking solution and incubated overnight at 4°C. Following
overnight incubation, coverslips were again rinsed thrice with 1X PBS and incubated with
secondary antibodies for 2-4hrs at RT in the dark. Coverslips were adequately rinsed prior to
coverslip mounting using Prolong Gold Antifade Mountant with DAPI (Fisher P36931). Primary
antibodies used included Nestin (Novus MAB1259), MAP2 (Fisher MA5-12823), vGLUT1
(Sigma AB5905), GLUR1 (Fisher PA5-111797), and ctip2 (Abcam ab18465). Secondary
antibodies utilized were Goat anti-Rabbit Secondary Antibody Alexa Fluor 568 (ThermoFisher A11011), Goat anti-Mouse Secondary Antibody Alexa Fluor 568 (ThermoFisher A-11004), Goat
anti-Rabbit Secondary Antibody Alexa Fluor 488 (ThermoFisher A11008), Goat anti-Mouse
Secondary Antibody Alexa Fluor 488 (ThermoFisher A-11001), Goat anti-Rat Secondary
Antibody Alexa Fluor 488 (ThermoFisher A-11006), and Goat anti-Guinea Pig Secondary
Antibody Alexa Fluor 488 (ThermoFisher A-11073). Imaging was performed using confocal
microscopy (Zeiss, Axioskop 2, Germany).

Whole-Cell Patch Clamp Electrophysiology
Whole-cell patch clamp recordings were taken using a Zeiss, upright microscope (Axioscope, FS2,
Carl Zeiss, Germany) equipped with a multiclamp 700B amplifier [177]. The intracellular patch
solution consisted of 140 mM K-gluconate, 4 mM NaCl, 0.5 mM CaCl2, 1 mM MgCl2, 1 mM
EGTA, 5 mM HEPES Acid, 5 mM HEPES base, and 5 mM Na2ATP [151]. Spontaneous neuronal
firing, induced repetitive firing, and sodium and potassium currents were evoked as described in
Caneus et al. [62]. Data was processed using Clampfit, Microsoft Excel, and GraphPad Prism.
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Statistical analysis was determined using Student’s t-test or One-Way ANOVA and Tukey’s posthoc analysis.

MEA
MEAs were fabricated and surface patterned as described in Autar et al. [151]. Following surface
patterning, MEAs were coated using a 0.01% poly-L-ornithine solution (Sigma 27378-49-0) for
1hr at RT. Surfaces were subsequently rinsed thrice with 1X PBS before being incubated overnight
at 4°C with a 3.33g/mL laminin (Fisher 23017015) solution. Surfaces were warmed to 37°C in
the incubator, and the laminin solution was aspirated immediately prior to cell seeding. WT control
cortical neurons were seeded on MEAs at a plating density of 400cells/mm 2, PSEN1 cortical
neurons at 200cells/mm2, PSEN2 and ApoE4 cortical neurons were both seeded at 1000cells/mm2
to compensate for cell loss due to line viability.

LTP Induction
MEA recordings were taken using a multi-channel systems (MCS) rig. LTP was induced via a
100Hz high-frequency stimulation protocol of 10 repetitions of 4X biphasic 500mV, 5ms pulses
[62, 69, 151]. A pre-stimulation baseline was recorded for 5 minutes preceding HFS. All
recordings following LTP were also taken for 5 minutes, and normalized frequency comparisons
were used for determining LTP.
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MEA Analysis
Raw MEA data was filtered through a second order Butterworth 100Hz high-pass filter. Only
events crossing a threshold of +/- 5 standard deviations from the noise were taken as signal [251].
Any spikes co-occurring on more than 2 channels at the same millisecond time stamp were
eliminated as artifacts [62, 151]. A signal template was designed using eliminated signals
following lidocaine addition to develop a principal component analysis filter to further eliminate
system noise. Data was processed using Microsoft Excel and GraphPad Prism. Statistical analysis
was determined using Student’s t-test or One-Way ANOVA and Tukey’s post-hoc analysis.
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Figures

Figure 19: Characterization of Accelerated Maturation and Apoptosis in Mutant Lines. All cortical
neuron lines showed typical phase morphology at 14 DIV (A). The mutant lines at 14 DIV had differing
expression of neuroprogenitor protein Nestin and neuronal cytoskeletal protein MAP2, suggesting differing
maturation timelines (B), and decreased cell viability overtime indicating increased apoptosis (C). Scale
bar = 100m.
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Figure 20: Characterization of Cortical Neuron Character Via Immunocytochemistry.
Immunocyotochemical analysis revealed that all lines showed successful expression of layer V cortical
neuron transcription factor ctip2 (green) at 28 DIV. Neurons also expressed mature neuronal marker
microtubule associated protein 2 (MAP2, red). Coverslips were counterstained with DAPI for nuclear
visualization. Scale bar = 100m.
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Figure 21: Characterization of Neuronal Synapses via Immunocytochemistry. Immunocytochemical
staining depicting synaptic connectivity in WT and AD lines at 28 DIV. Pre-synaptic and excitatory
neuronal marker vesicular glutamate 1 (vGLUT1, green) illustrates synaptic puncta. Post-synaptic marker
GLUR1 (red) highlights a subunit of the AMPA glutamate receptor. Scale bar = 100m.
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Figure 22: Whole-Cell Patch Clamp Recordings of Spontaneous Neuronal Firing Overtime.
Representative traces of gap-free spontaneous neuronal activity of WT and AD neurons on (A) 14 DIV, (B)
21 DIV, and (C) 28 DIV. Graphs detailing neuronal firing in patch clamp experiments on (D) 14 DIV, (E)
21 DIV, and (F) 28 DIV portraying hyperactivation in PSEN1 and PSEN2 cortical neurons at 14 DIV that
is also present in the former at 21 DIV and is statistically significant compared to WT control cortical
neurons, that ultimately drops significantly at 28 DIV. Statistical significance was determined via Student’s
t-test, * p<0.05, ** p<0.01, *** p<0.001.
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Figure 23: Whole-Cell Patch Clamp Recordings of Induced Repetitive Neuronal Firing Overtime.
Representative traces of induced, repetitive neuronal activity of WT and AD neurons on (A) 14 DIV, (B)
21 DIV, and (C) 28 DIV. Graphs detailing neuronal firing in patch clamp experiments on (D) 14 DIV, (E)
21 DIV, and (F) 28 DIV depicting the hyperactivation present in PSEN1 cortical neurons at 14 and 21 DIV
that is significantly reduced in PSEN1 and PSEN2 cultures compared to WT controls at 28 DIV. The ApoE4
cortical neurons also experienced hyperactivation at 21 DIV, but were otherwise not significantly different
than the WT control. Statistical significance was determined via Student’s t-test, * p<0.05, ** p<0.01, ***
p<0.001.
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Figure 24: Whole-Cell Patch Clamp Recordings of Sodium Currents Overtime. Representative traces
of neuronal currents at 28 DIV for (A) WT Control, (B) PSEN1, (C) PSEN2, and (D) ApoE4. Graphs
detailing neuronal firing in patch clamp experiments on (E) 14 DIV, (F) 21 DIV, and (G) 28 DIV illustrating
the hyperactivity present in the PSEN1 and PSEN2 cortical neurons at 14 DIV that exhibit a marked
decrease at 28 DIV compared to the WT control cortical neurons. Statistical significance was determined
via Student’s t-test, * p<0.05, ** p<0.01, *** p<0.001.

92

Figure 25: Induction of Long-Term Potentiation in AD Lines at 21 DIV. Representative traces of
neuronal activity on MEAs at 21 DIV for baseline (left), immediate post-LTP stimulation (middle), and 1hr post-LTP stimulation (right) for (A) WT control cortical neurons, (B) PSEN1 cortical neurons, (C)
PSEN2 cortical neurons, and (D) ApoE4 cortical neurons. (E-H) Graphs quantifying LTP induction and
maintenance normalized to baseline levels indicating that LTP could not be maintained in WT control
cortical neurons, but LTP persistence at 1-hour was significant for the PSEN1 and PSEN2 cortical neurons.
Statistical analysis was determined via One-Way ANOVA and Tukey’s post-hoc analysis, * p<0.05, **
p<0.01, *** p<0.001.
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Figure 26: Induction of Long-Term Potentiation in AD lines at 28 DIV. Representative traces of
neuronal activity on MEAs at 28 DIV for baseline (left), immediate post-LTP stimulation (middle), and 1hr post-LTP stimulation (right) for (A) WT control cortical neurons, (B) PSEN1 cortical neurons, (C)
PSEN2 cortical neurons, and (D) ApoE4 cortical neurons. (E-H) Graphs quantifying LTP induction and
maintenance normalized to baseline levels, indicating that, while LTP persistence is present in WT control
cortical neurons, LTP was not maintained at 1-hour for the PSEN1, PSEN2, and ApoE4 lines. Statistical
analysis was determined via One-Way ANOVA and Tukey’s post-hoc analysis, * p<0.05, ** p<0.01, ***
p<0.001.
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Table 1: Formulation of N2B Media
Component
DMEM/F-12
Human apo-transferrin
Insulin
D-(+)-Glucose, Anhydrous
Progesterone
Putriscine
Na+ Selenite

N2B Media
Company
Catalog #
Fisher
21041-025
R&D
3188-AT-001G
Millipore
407709-50MG
Sigma
G8270
Sigma
P-8783
Sigma
P-5780
Sigma
214485-5G
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Concentration
1.25 M
4.3 M
8.65 mM
20 nM
100 M
30 nM

Table 2: Formulation of Differentiation Media I
Differentiation Media I
Component
Company
Catalog #
N2B
SB431542
TOCRIS
1614
LDN193189
TOCRIS
6053
DMH-1
TOCRIS
4126
DKK1
Fisher
5439-DK-010
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Concentration
6 M
0.1 M
2 M
10 ng/ml

Table 3: Formulation of Differentiation Media II
Differentiation Media II
Component
Company
Catalog #
N2B
SB431542
TOCRIS
1614
LDN193189
TOCRIS
6053
DMH-1
TOCRIS
4126
Cyclopamine
Millipore
239803
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Concentration
6 M
0.1 M
2 M
5 M

Table 4: Formulation of Differentiation Media III/Maintenance Media
Differentiation Media III/Maintenance Media
Component
Company
Catalog #
Concentration
Neurobasal
Fisher
21103049
1X
Glutamax
Fisher
35-050-061
1X
N2 supplement
Fisher
17502048
1X
B27 (w/o VitA)
Fisher
12587-010
20ng/ml
BDNF
Cell Sciences
CRB600D
20ng/ml
GDNF
Cell Sciences
CRG400E
200nM
Ascorbic acid
StemCell
72132
1 M
cAMP
Sigma
A9501-1G
1 g/ml
Laminin
Sigma
L2020
1X
Antibiotic-Antimycotic
Fisher
15240-062
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Table 5: Formulation of BrainPhys Media
Component
BrainPhys Base Media
N2-A Supplement
SM1 Supplement
BDNF
GDNF
Ascorbic acid
cAMP
Laminin
Antibiotic-Antimycotic

BrainPhys Media
Company
StemCell
"
"
Cell Sciences
Cell Sciences
StemCell
Sigma
Sigma
Fisher
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Catalog #
05793
"
"
CRB600D
CRG400E
72132
A9501-1G
L2020
15240-062

Concentration
1X
1X
20ng/ml
20ng/ml
200nM
1 M
0.5 g/ml
1X

Table 6: Line and Genotyping Details of AD iPSCs
Line
WT Control
PSEN1
PSEN2
ApoE4

Line Details
ND41865
CS40iFAD
CS08iFAD
BIONi010-C-4

Sex
Male
Male
Female
Male
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Age
64
56
81
N/A

Mutation
N/A
ALA246GLU
ASN141ILE
N/A

ApoE Genotype
E2/E3
E3/E3
E3/E3
E4/E4

CHAPTER SIX: GENERAL DISCUSSION
Alzheimer’s disease is described as a loss of cognition from the presence of Aβ42 plaques
in the brain, generally characterized in models for AD assessment as a loss of neuronal function,
both at the cellular and the synaptic level [252-256]. There are several notable mechanisms for the
onset of AD, with the most well-known being the loss of synaptic networking through the
agglomeration of senile Aβ42 [4], which also potentially onset Tau neurofibrillary tangles [257].
However, neurodegeneration in AD can also be exacerbated by neuroinflammation [6], Ca+2
dysfunction [258, 259], and the accrual of reactive oxygen species [36]. Due to limited neuronal
cell sources for developing in vitro models of AD, human-derived iPSCs were utilized to develop
a serum-free differentiation protocol, and the maturation of the neuronal culture was tracked to
optimize the timepoint for evaluating LTP, the in vitro correlate for learning and memory [260].
Once validated, this system could be further employed to SAD and FAD models for assessing
cognitive deficits.
An iPSC to cortical neuron differentiation protocol was first established and characterized
for LTP proficiency [151]. Serum-free medium formulations were used to initiate cortical neuron
differentiation starting with dual-SMAD inhibition [74], inducing cortical neuron character
mimicking the development of neurons in vivo. Following differentiation, neurons were evaluated
throughout maturation, where they were characterized for common neuronal and cortical neuron
markers and assessed for neuronal function using whole-cell patch clamp (Figures 1-3). Once the
successful differentiation of cortical neurons was confirmed, neuronal networks were cultured on
MEAs to assess neural population dynamics and LTP (Figure 4-5). It was discovered that the
neurons also simulated immature inhibitory character [89, 261]. It was established that neurons
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did not exhibit fully glutamatergic character until 30-40 DIV, and therefore could not maintain
persistent LTP for 1-hour until this timepoint in maturation, due to possession of GABAergic
neuronal character, impeding LTP capabilities at earlier timepoints (Figure 6).
Once validated, this model could be utilized to evaluate drug efficacy in neuronal culture.
This iPSC-cortical neuron culture was used to establish a model of sporadic AD (SAD), where the
neuronal cultured was supplemented with Aβ42 oligomers to incite the AD phenotype,
characterized in our culture as an impedance of LTP. Following the confirmation of all drug targets
in the iPSC-cortical neuron culture (Figure 8), neurons were cultures on MEAs for the evaluation
of the ability of each drug to block the neurotoxic effects of Aβ42 (Figure 9). Whole-cell patch
clamp electrophysiology was used to accompany the assessment of network integrity on MEAs.
Donepezil is an acetylcholinesterase inhibitor, which works to increase the availability of
acetylcholine within the synaptic cleft to preserve neuronal function [50]. It was observed to rescue
Na+ currents and spontaneous firing (Figure 10). Saracatinib inhibits the Fyn kinase, which is
directly responsible for the amplified formation of Aβ42 plaques, and can be exacerbated by the
presence of Aβ42 dosed in the culture media [52, 185]. Consequently, the co-administration of
Saracatinib with Aβ42 oligomers significantly aided Na+ currents, neuronal firing frequencies, and
action potential amplitudes (Figure 11). Memantine specifically targets the NMDA receptor to
counteract excitotoxicity-induced synaptic decline [49], and was shown to rescue neuronal firing
amplitudes (Figure 12). Lastly, Rolipram, which increases intracellular cAMP by inhibiting its
breakdown [53], displayed significant preventative effects on neuronal firing amplitudes (Figure
13). Chiefly, all the evaluated drugs were shown to significantly maintain LTP, preventing the
Aβ42 oligomer-induced loss of synaptic function, in our neuronal systems (Figures 10-13).
102

Neurodegeneration onset of AD is characterized by a notable loss of synapse integrity
[188]. To further enhance the capability of our system to evaluate synaptically transmitted LTP
deficits, a surface pattern was employed to the MEAs to initiate synaptic pairing of neuronal
populations (Figures 14-16). It was observed that LTP could be induced within a neuronal
population from performing high frequency stimulation on its synaptically paired population,
which was not found to be significantly different than LTP induced through direct stimulation
(Figures 17-18).
The establishment of an hiPSC-cortical neuron protocol could be further expanded to
encompass several known AD genetic mutation and predispositions, the mechanisms of which
have been widely theorized but minimally explored. The resulting differentiation of our PSEN1,
PSEN2, and ApoE4 cortical neurons have exhibited phenotypes consistent with known hypotheses
for this mutation and other literature results. Enhanced neurogenesis was present in the PSEN1
mutant cortical neurons alongside a proclivity for self-differentiation [217], and hyperexcitability
was characteristic in both the whole-cell patch clamp and MEA results (Figures 20-26). This
hyperexcitability phenotype fueled the excitotoxicity within the culture, as the PSEN1 and PSEN2
neuronal cultures declined more quickly than the WT, and could not sustain LTP at the timepoint
in which the WT neurons were established as a mature culture. The ApoE4 phenotype was
observed in a similar fashion. While the differences were not significantly different from the WT
control, patch clamp recordings confirmed the accelerated maturation phenotype previously cited
in literature. This trend was mimicked in LTP recordings, indicating synaptic decline, as persistent
LTP was achievable at 21 DIV, but was not present at later timepoints.
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This model aimed to provide a biologically relevant system for assessing drug efficacy at
the preclinical stage by establishing a functional disease phenotype. In this study, it was shown
that the co-administration of AD therapeutic treatments blocked the neurotoxic effects of Aβ42
oligomers, and the previously validated iPSC-cortical neuron differentiation protocol could be
adapted for the development of patient-derived neuronal cultures. The use of microelectrode arrays
enables the development of minimally invasive, patient-specific neural networks that can be
assessed for synaptic communication. The establishment of a human-based, in vitro, iPSC-derived
cortical neuron model provides an apparatus for preclinical drug evaluation of CNS diseases.
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